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Gene Expression and CD4+ T Cell Susceptibility to SIV 
Abstract 
HIV and its simian counterpart SIV infect CD4+ T cells; however, not all CD4+ T cells 
are equally vulnerable to infection.  Despite decades of research, a complete molecular 
description of a CD4+ T cell susceptible to infection is still lacking. We hypothesized that the 
comprehensive expression analysis of a large panel of genes predicted to positively or negatively 
influence viral replication would provide insights into the molecular mechanisms that underlie 
differences between subsets of CD4+ T cells in their susceptibility to lentiviral infection. We 
generated a panel of genes predicted to positively or negatively influence viral replication by 
mining published data with multiple bioinformatic methods. Using high-throughput microfluidic 
quantitative real-time PCR, we measured expression of 174 genes in defined subsets of naïve and 
memory CD4+ T cells from peripheral blood and jejunum. We observed significant modulation 
of genes in response to memory differentiation, anti-CD3/CD28, and type I interferon 
stimulation. Despite broad similarities in expression patterns between peripheral blood and 
jejunum, the highly susceptible CCR5+ transitional memory CD4+ T cells from jejunum had 
lower total expression of restriction factors relative to the same subset in peripheral blood. 
Expression of most restriction factors increased during acute SIV infection in all CD4+ T cell 
subsets. 
 Gene expression in single cells is known to differ from the average expression obtained 
by bulk methods. We analyzed over 300 single memory CD4+ T cells from rhesus intestinal 
tissue during acute SIV infection and identified individual infected and uninfected cells. 
Expression of 96 genes was compared, revealing PD-1 and CXCR5 as the most differentially 
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expressed. Together these genes define T follicular helper cells (Tfh); however, Tfh cells have 
not been previously described in jejunum tissue. We verified the presence of this population and 
found many phenotypic, transcriptional, and functional similarities of this novel jejunal cell 
population to classical Tfh cells from lymph nodes. Finally, we found these cells were highly 
SIV-infected, at much higher levels than total memory CD4+ T cells. Overall, these studies 
highlighted determinants of susceptibility, identified a novel Tfh-like cell population, and 
described a prime target for SIV infection during acute infection. 
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1.A. Scope of HIV/AIDS global epidemic 
 Acquired Immune Deficiency Syndrome (AIDS) was initially identified in 1981 as 
unusual opportunistic infections struck young homosexual men 1. A lentivirus, now called 
Human Immunodeficiency Virus 1 (HIV-1), was identified as the causative agent in the 
following years 2-4. The pandemic form of HIV-1, called group M, has infected over 65 million 
people since 1990 and caused over 34 million deaths 5. Currently, there are over 36 million 
people living with HIV and over 2 million new infections worldwide in 2015 6. While global 
rates of infection have dropped from their late 1990s peak, areas like Eastern Europe and Central 
Asia are still seeing rising transmission rates 5. Even in wealthy countries such as the United 
States, HIV remains a tremendous burden. Over 1.2 million people are living with HIV infection, 
and over 650,000 people with an AIDS diagnosis in the US have died overall 7,8.  
 Antiretroviral drug treatment has had a dramatic impact on disease outcomes. Generally a 
mixture of three drugs, combination antiretroviral therapy suppresses viral replication reducing 
plasma viral load to levels undetectable with standard assays (<50 RNA copies/mL) in most 
patients 9. This results in significant reconstitution of circulating CD4+ T cells 10, decreases in 
transmission, decreases in opportunistic infections, and increases in lifespan. Strikingly, a UK 
cohort with successful treatment resulting in good CD4+ T cell count and low viral load has been 
found to have normal life expectancy 11.  
Despite significant progress in treatment, many challenges still remain. Access to 
treatment, especially in less wealthy countries, remains challenging. Despite adding about 2 
million people to the total currently on treatment in 2014, the rate of new infections still equals 
or exceeds the rate of new people on treatment 6. Due to latency and the lifelong nature of 
infection, patients must continually remain on antiretroviral drugs. Resistance to antiretroviral 
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drugs is also a significant concern, especially if adherence to proper dosing is not complete. The 
cost of treatment is also a significant barrier, especially for treatment of HIV-infected people in 
developing countries. 
Over 35 years from the start of the epidemic and despite significant effort, there is still no 
effective HIV vaccine. Studying the early events of HIV in humans is challenging since 
individuals may not know they are infected, the acute phase presents with mild symptoms 12, and 
many of the critical pathogenic events occur in hard to study mucosal tissue 13. Better 
understanding of the acute phase of pathogenic lentiviral infections, including characteristics of 
the early cellular targets of infection, could lead to progress in treatment, vaccine development, 
and cure research. 
 
1.B. Large-scale screens for host lentiviral dependency factors 
 Retroviruses have complex lifecycles, yet only encode a small number of proteins and are 
therefore reliant on many cellular proteins for successful infection. Some host proteins that 
facilitate different steps of the retroviral lifecycle (termed “dependency factors”) have been well 
studied while others have only been identified in screens with little further study to date. One 
widely used method to identify host factors required for viral replication is a genome-wide small 
interfering RNA (siRNA) screen. In general, RNA interference is used to knock down expression 
of a particular gene, and a resultant phenotype of reduction in viral replication/infectivity signals 
that the gene was important for the viral replication cycle 14.  Four such studies have been 
performed for HIV, each using different conditions 15-18. Brass et al. 17 used HeLa cells 
expressing CD4 transfected with four siRNAs per gene 72 hours before infection with HIV-1 
IIIB. Cells were scored 48 hours later for p24 capsid, and supernatants were tested in new cells 
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with an integrated tat-responsive β-galactosidase reporter for infectious virion production. Konig 
et al. 16 used 293T cells, transfected with about 6 siRNAs per gene 48 hours before infection with 
VSV-G pseudotyped replication defective HIV-1 expressing luciferase. Cells were scored 24 
hours later for luciferase and hits were genes that reduced luciferase expression more than 45%. 
Zhou et al. 15 used HeLa cells expressing CD4 and a β-galactosidase reporter, transfected with 
about three siRNAs per gene 24 hours before infection with HXB2 replication competent HIV-1. 
Cells were scored both 48 and 96 hours later for β-gal reporter activation. Finally, Yeung et al. 18 
used the Jurkat T cell line, a short-hairpin RNA (shRNA) library with 3-5 shRNAs per gene to 
stably knock down expression, infection with NL4-3 strain of HIV-1, and survival of cells as a 
read out. 
 These four screens alone identified over 1100 genes, and when combined with other 
smaller studies, nearly 10% of the human genome has been implicated in the HIV lifecycle 19. 
There is extremely little overlap between each of the studies, with less than 7% overlap between 
any pairwise combination of screens 19. This could be due to a number of reasons, such as 
different target cells, siRNA libraries, screen conditions, and different filtering of genes whose 
depletion was toxic. Additionally, not all required genes are likely identified by these screens as 
they are in cell lines not the natural in vivo target cells. Unannotated genes or microRNAs would 
be missed, and genes with redundant functions would also be overlooked as only one gene is 
depleted at a time 20. Many of the identified genes could also be off-target effects, for example if 
the siRNA depleted multiple genes. To minimize potential off-target effects, one of the screens 17 
has been repeated using multiple independent siRNA libraries identifying 108 genes 21. Nearly 
50% of these 108 genes had also been identified in the original screen. Drawbacks aside, large-
scale screens have provided valuable insight into host genes required for viral replication.  
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1.C. Interactions between HIV/SIV and host dependency factors 
Binding and Entry 
The HIV replication cycle (Figure 1.1) begins with adhesion of virus to the host cell, 
binding of the viral envelope and receptors, fusion of the cell and viral membranes, and delivery 
of the viral core into the cytoplasm. Initial attachment of the virus to the cell surface can be 
relatively non-specific and, while non-essential, brings Env into close proximity with viral 
receptors. Known cellular factors that could contribute include heparin sulfate proteoglycans, 
which interact non-specifically 22, dendritic cell-specific intercellular adhesion molecular 3-
grabbing non-integrin (DC-SIGN) 23, and α4β7 24,25. The primary cellular receptor that the Env 
protein of HIV and SIV bind is the CD4 molecule on the cell surface 26,27. Binding of the Env 
trimer causes conformational changes allowing coreceptor binding, mediated in part by the V3 
loop 28. The most common coreceptors for HIV are CCR5 and CXCR4 29. SIV in rhesus 
macaques also primarily uses CCR5 30, although other coreceptors such as GPR15 and STRL33 
can also be used 31. Coreceptor binding triggers fusion with the host cell membrane by insertion 
of the gp41 hydrophobic fusion peptide, subsequent six-helix bundle formation, lipid mixing, 
and formation of the fusion pore 32.  
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Reverse Transcription 
After fusion, the viral core enters the nucleus, and reverse transcription of the viral 
genome by the viral enzyme reverse transcriptase (RT) occurs. Although some host factors may 
play a role in reverse transcription, the polymerase and RNase H activities that are necessary and 
sufficient are present in RT itself. First, the plus-strand RNA genome is bound by a host tRNA 
primer near the 5’ end of the genome at a site called the primer binding site 34. In the case of 
HIV, the host tRNA is Lys3 35. RT initiates reverse transcription and generates minus strand 
DNA, while the RNase H activity degrades the RNA template. The newly synthesized DNA is 
transferred to the 3’ end of the viral RNA and minus strand DNA synthesis continues along the 
 
Figure 1.1. HIV replication cycle 33. 
The basic steps of an HIV or SIV replication cycle are illustrated including binding and entry, 
fusion, reverse transcription, integration, production of new viral transcripts and protein, and 
finally budding and virion maturation. 
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genome. A polypurine tract is resistant to RNase H cleavage and serves as the primer for plus-
strand DNA synthesis 36. Plus-stand synthesis progresses until the nucleotides of the tRNA are 
copied allowing for removal of all but one A of the tRNA by RNase H activity 37. The second 
(plus-strand) transfer occurs and the ends of both the plus and minus strands are extended to 
complete the double-stranded linear viral DNA. 
Uncoating and Nuclear Import 
 Reverse transcription in cells occurs in a reverse transcription complex (RTC) containing 
multiple viral proteins including matrix, capsid, nucleocapsid, integrase (IN), and VPR 38. 
Transition of the RTC into a pre-integration complex (PIC) occurs with uncoating, or changes in 
the structure of the viral capsid core. Uncoating is necessary since HIV infects non-dividing cells 
and the viral capsid is approximately double the size of the nuclear pore. Many aspects of 
uncoating including the location, timing, and relationship to reverse transcription are still under 
investigation 39. Studies have suggested both removal of capsid prior to nuclear import 40 as well 
as some capsid remaining associated with the viral complex inside the nucleus 41.  
The host protein cyclophilin A (CypA) has long been known to interact with the capsid 
protein 42,43, specifically a conserved proline-rich loop on the HIV-1 capsid protein 44. CypA is a 
host peptidyl prolyl isomerase that can be incorporated into virions 45 but seems to have more of 
an effect in the cytoplasm of the target cell where it can promote infection in some cell types 46. 
Although it seems clear that CypA plays a part in uncoating or in some step in the replication 
cycle occurring concurrently with uncoating, the current collection of data make it difficult to 
assign a single critical role 47. 
Several cellular factors have been shown to associate with the PIC including HMG I(Y) 
48 and LEDGF/p75 49. Many nuclear pore components have been found to be associated with 
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HIV. In fact, three siRNA dependency factor screens were enriched in genes annotated as 
involved in ‘‘Nuclear Pore / Transport’’ (21–24 genes each), which could participate in 
processes including the nuclear import of the HIV PIC, export of viral RNAs, or synthesis of 
other factors 19. Verified cellular interactors at the level of nuclear import include TNPO3 50,51, 
CPSF6 52, NUP358/RANBP2 53,54, NUP153 55 and others.  
Integration 
 Integration is the covalent attachment of the viral DNA to host cell DNA resulting in 
formation of the provirus and is mediated by the viral IN protein. The catalytic steps of 
integration are well understood. In general they include 3’ end processing, attack of a pair of 
phosphodiester bonds separated by five nucleotides in the target DNA, joining of the 3’ ends of 
viral DNA to the 5’ ends of target DNA, removal of the two unpaired bases at the 5’ ends of the 
viral DNA, filling in the gaps, and ligation of the 5’ ends of the viral DNA to target DNA 56. The 
viral IN protein is responsible for catalyzing the 3’ end processing and DNA strand transfer steps 
while cellular enzymes are thought to complete the process. In vitro integration reactions have 
been shown to be enhanced by many host factors, including LEDGF/p75, BAF, HMGA, HMGB, 
Ini-1, and YY1, though the in vivo importance of these interactions is unclear 56. Additionally, 
several cellular chromatin proteins such as EED, SUV39H1, HP1y, among others have been 
implicated in integration 57, and cellular DNA repair enzymes likely participate in the final steps 
of integration, though the important components in vivo have not been identified.  
 The site of integration is not random, with HIV preferring to integrate in active 
transcription units 58,59. Viral IN, the chromatin structure, and other genomic features as well as 
cellular factors help to shape this preference. In particular, the LEDGF/p75 protein has been well 
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characterized to increase the efficiency of integration and mediate targeting to active 
transcription units by tethering IN to host chromatin 60-62.  
 
Transcription and Translation 
 The HIV provirus is a transcription template from which spliced mRNAs for viral protein 
production and unspliced genomic RNA for packing into new virions is produced. As the virus 
does not have its own transcription machinery, it relies on the host cell. Although the viral LTR 
is a promoter; early experiments showed a transactivating factor, called Tat, needed to interact 
with the transactivation-responsive region (TAR) to allow for efficient transcription 63,64. Tat is 
one of the first transcripts produced and works by interacting with the host protein P-TEFb 65-67, 
which is an elongation factor complex. Tat and P-TEFb work together to remove blocks to 
elongation by host NELF and DSIF proteins 68,69 while enhancing RNAP II processivity through 
phosphorylation of its C-terminal domain 70. In addition to the core promoter region, HIV has an 
enhancer region with NF-kB binding motifs 71 that members of the NF-kB 72 and NFAT 73 family 
can bind, supporting replication in primary cells 74. Multiple subunits of the mediator complex 
were identified in two or more siRNA screens including MED4, 6, 7, 14, and 28 19. This complex 
links transcriptional activator proteins to the RNA polymerase II transcription apparatus, 
allowing transcriptional activation. Co-immunoprecipitation suggests an interaction with Tat 75. 
Other host proteins with unknown mechanisms of action, such as ZNRD1 76, also influence 
transcription. 
 HIV transcripts undergo splicing using the host splicing machinery (a large complex 
called a spliceosome) to produce the full range of mRNAs encoding viral proteins. Unspliced 
and incompletely spliced transcripts, which are normally degraded in the nucleus, are exported 
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with the help of the viral Rev protein binding the Rev-responsive element in the env gene RNA 
77,78. Cellular nuclear import and export pathways are utilized by Rev, and interactions with 
importin-β, eIF-5A, several FG repeat-containing nucleoporins including Rip/Rab, RanGAP, 
RanBP1, and CRM1/exportin1 have been identified 79. Transcripts undergo 3’ processing and 
polyadenylation using many host factors such as CPSF, CstF, CFIm, CFIIm, and poly(A) 
polymerase 80. mRNAs are then translated into proteins using normal cellular translational 
machinery. Some Rev cofactors such as DDX3 have also been implicated in translational 
regulation 81. 
Assembly and Budding 
 Virion production is accomplished by assembling and packaging essential components, 
budding where the virion crosses the plasma membrane and acquires its lipid membrane, and 
maturation where the virion becomes infectious with structural changes. Gag and Gag-Pro-Pol 
polyproteins are synthesized in the cytosol and traffic to microdomains in the plasma membrane. 
This requires interaction with many components of intracellular trafficking pathways including 
AP-1 82, AP-2 83, AP-3 84, KIF4 85, and ABCE1 86. Gag molecules polymerize onto nucleation 
sites of Gag-RNA complexes, and interactions with matrix promotes Env incorporation. Two 
copies of noncovalently dimerized, capped, and polyadenylated full-length RNA genome are 
incorporated into the virion 87.  Gag assembly leads to immature lattice formation, and the virus 
then uses the host ESCRT pathway to catalyze release 88. Host proteins TSG101 89 and ALIX 90 
are recruited to sites of budding by Gag late domain motifs, and other components of the host 
ESCRT machinery such as ESCRT-III (specifically CHMP2 and 4 families) and VSP4 
complexes are recruited to complete membrane fission 91. Concurrently or shortly after budding, 
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viral maturation occurs by viral protease cleaving Gag and Gag-Pro-Pol polyproteins which then 
rearrange extensively to create mature infectious virions. 
 
1.D. Interactions between HIV/SIV and host restriction factors 
 A strict definition of a restriction factor is a host gene that directly and dominantly causes 
a significant decrease in viral infectivity, has a virally encoded counter-measure, shows signs of 
rapid evolution, and has expression linked to the host’s innate immune response (e.g. is 
interferon induced) 92.   In a more general sense, a putative restriction factor is any host molecule 
that can interfere with successful completion of the viral replication cycle, as described here.  
Binding and Entry 
 Blocking the viral envelope protein from interacting with its coreceptors can reduce the 
ability of virus to enter a cell. Though it is not considered a restriction factor, the level of 
autocrine CCR5-binding chemokine production (MIP-1α and MIP-1β) has been shown to 
influence susceptibility to infection 93. 
 A family of proteins that appear to act at the entry step in HIV infection are the IFITMs 
94. IFITM1, 2, and 3 are ubiquitously expressed, and IFITM1 and 3 respond to interferon 
stimulation 95. Though the molecular mechanism behind the IFITM restriction action remains to 
be elucidated, one suggestion is that IFITM proteins incorporate into the viral membrane and 
inhibit membrane fusion 96. Another proposed model is impairing Env protein incorporation in 
producer cells 97. Rhesus macaque IFITM proteins are poorly annotated in the existing rhesus 
genome 98,99. However, other non-human primate IFITMs show activity against HIV-1 and SIV 
strains, suggesting a non-species-specific activity 100. 
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 Two recently identified host proteins, SERINC3 and SERINC5, appear to restrict HIV at 
entry or just post-entry and are counteracted by the Nef protein 101,102. The studies used 
independent methods (proteomics and expression profiling) to identify the targets for Nef 
infectivity enhancement. When viral particles are produced without Nef, large amounts of the 
SERINCs are incorporated impairing the fusogenicity and potentially early post-entry steps in 
the replication cycle. When Nef is present in producer cells, SERINCs are redistributed from the 
plasma membrane into an intracellular Rab7-postive membrane compartment. Despite their 
apparent antiviral activiety, SERINC3 and 5 do not appear to be under positive selection in 
primates (including rhesus macaques) unlike confirmed restriction factors APOBEC3G/F, 
TRIM5α, or BST-2/Tetherin 103. Nef from SIVmac239 was able to counteract human SERINC5 
in human cells 102, though whether it can counter rhesus SERINCs in rhesus cells remains to be 
investigated.  
Reverse Transcription 
 The host protein SAMHD1 can reduce the efficiency of reverse transcription by reducing 
the cellular pool of dNTPs with dNTPase activity 104,105. The lack of sufficient dNTPs leads to a 
failure to complete reverse transcription quickly enough to avoid particle disintegration and 
degradation. This restriction is cell type-specific, since myeloid cells 106 and quiescent CD4+ T 
cells 107,108 have lower steady-state levels of dNTPs than activated replicating cells. The viral 
protein Vpx, found in many SIV strains and HIV-2 though not HIV-1 109, counteracts SAMHD1 
by targeting it for proteosomal degradation by ubiquitination through the CUL4A/DDB1/DCAF1 
pathway 110-112 . The regulation of SAMHD1 activity is still under investigation; however, 
phosphorylation by cellular CDK proteins 113 and p21 114, an inhibitor of CDK2, appear to be 
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involved. As CDK protein expression varies during the cell cycle, other layers of regulation are 
likely involved as well. 
The APOBEC family of restriction factors acts by deaminating C-to-U bases in viral 
cDNA upon initiation of reverse transcription. This results in G-to-A hypermutation in viral 
sequences 115. In cells producing virus, APOBEC3D, F, G, and H can package into virions, and 
so are poised to function as soon as reverse transcription occurs 116. All lentiviruses, except 
equine infectious anemia virus, express a Vif protein optimized to neutralize the restrictive 
APOBEC3 proteins of their host species 117. Vif overcomes APOBEC3 restriction by binding 
host protein CBFβ and recruiting a host E3 ubiquitin ligase complex (RBX2, CUL5, ELOB and 
C) to target them for degradation by the 26 S proteasome 92,118.  
First identified in a large scale RNAi screen for HIV restriction factors 119, RPRD2 / 
REAF has been found to act at an early stage in the viral life cycle reducing early and late 
reverse transcripts which subsequently impacts the level of integration 120. The mechanism of 
action is still under investigation, although its association with viral nucleic acids suggests it may 
prevent reverse transcription. 
Uncoating and Nuclear Import 
 A screen for rhesus macaque genes that could restrict HIV-1 infection when expressed in 
human cells first identified TRIM5α 121. The mechanism of action is still under investigation, but 
it is known that TRIM5α binds directly to retroviral capsids 122. Models have been proposed that 
suggest an accelerated capsid fragmentation in the cytoplasm soon after entry, which disrupts 
reverse transcription complexes. However, proteosome inhibition that prevents TRIM5-promoted 
capsid disassembly restores reverse transcription but not infection 123, indicating this mechanism 
alone fails to account for the full inhibitory potential of TRIM5α. TRIM5 has also been proposed 
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to be a pattern recognition receptor for retroviral capsids as it can lead to a signaling cascade 
activating AP-1 and NF-kB-dependent genes 124. This could help to establish an antiviral state 
and account for restriction beyond capsid fragmentation.  
 TRIM5α is species-specific in its activity, with human TRIM5 being relatively 
ineffective against HIV-1 (though active against some other retroviruses), while TRIM5α from 
Old World monkey species generally inhibit HIV 121. This makes TRIM5α a barrier to cross-
species transmission of primate lentiviruses 125,126. 
 TRIM5 is part of a family of TRIM genes, many of which have been shown to have anti-
HIV activity 127 and to be interferon induced 128. Studies of other TRIM family members have 
shown inhibition at multiple stages in the HIV replication cycle 129,130. 
Recently, the interferon-inducible protein MxB / Mx2, was found to restrict HIV in a 
capsid-dependent manner 131-133. Reverse transcription occurred normally in overexpression 
systems, but integration was reduced. Precise mechanisms for restriction are still under 
investigation, but it appears that interaction with capsid is required and that dimerization of MxB 
molecules supports this interaction 134. 
Integration 
Not all viral DNA entering the nucleus becomes productively integrated, since dead-end 
pathways of both one- and two-LTR circles can be found. Inactivation of host cell 
nonhomologous end joining components Ku70/80, ligase IV, and XRCC4 blocks 2-LTR circle 
formation 135,136, the cellular MRN complex has been implicated in 1-LTR circle formation 137, 
and DNA repair enzymes XPB and XPD have been reported to inhibit replication 138. 
 Transcription and Translation 
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 Limited reports suggest the host protein ZC3H12A/MCPIP1 can reduce HIV infection by 
decreasing steady state levels of the viral mRNA though its RNase domain and that SIV Vpx 
does not counteract this protein 139,140. 
 Components of the exosome complex (EXOSC2, 3, and 10) were top hits in a large-scale 
siRNA screen for HIV restriction factors 119. RNA exosomes reside in the nucleus and cytoplasm 
and are involved in RNA quality control and decay, and so could reduce levels of HIV 
transcripts. 
 Viral translation can be inhibited by SLFN11 141. Wild-type isolates of HIV-1 have a 
different codon bias than the host cell, and the supply of tRNAs generally increases during HIV 
infection to account for HIV’s requirement for rarer tRNAs 142. SLFN11 can counteract HIV-
induced changes in tRNA levels by a direct interaction with tRNAs, thereby inhibiting viral 
protein production. 
Assembly and Budding 
 A verified host restriction factor that functions by impairing viral release, BST2 / 
tetherin, was discovered as the protein that accounts for the late-stage defect in Vpu-deficient 
HIV-1 particle release 143,144. Tetherin can incorporate into viral membranes and physically 
bridge particles to the cell plasma membrane, where captured virions can be internalized for 
lysosomal degradation 145. HIV-1’s Vpu protein recruits β-TrCP2, a component of the SKP1-
CUL-F box E3 ubiquitin ligase complex, leading to the down-regulation and degradation of 
tetherin 146. Viruses without vpu genes use alternative mechanisms to counteract restriction by 
tetherin, emphasizing the importance of overcoming this block to viral replication. SIVmac uses 
Nef  147 and AP-2 dependent endocytosis 148, while HIV-2 uses its Env protein and clatherin 
dependent internalization and sequestration 149 to counteract tetherin. 
16 
 
 
1.E. Rhesus macaques and SIV as a model system for humans and HIV 
Rhesus macaques (Macaca mulatta) and humans diverged evolutionarily about 25 
million years ago and share roughly 93% genomic sequence identity 99. Macaques exhibit greater 
similarity to humans in physiology, neurobiology, and susceptibility to infectious diseases than 
do rodents, which are separated from humans by more than 70 million years 99. Rhesus macaques 
are the most widely used nonhuman primate species in biomedical research, and a wealth of data 
exists on their physiology, endocrinology, and metabolism 150. Importantly, the proportions of 
the major intestinal T cell subsets in humans and normal macaques are very similar, making 
macaques a good model for critical phases of immunodeficiency virus pathogenesis 151. Of 
potential importance to this study, the similarity of T follicular helper (Tfh) cells appears greater 
between humans and non-human primates than between humans and mice. For example, the 
effects of STAT3 and 4 transcription factors on Tfh differentiation differ between humans and 
mice 152, and the cytokine Activin A was recently shown to drive human and rhesus macaque, 
but not mouse, Tfh differentiation, despite 100% sequence identity between human and mouse 
Activin A 153. 
Both SIVmac and HIV-1 are lentiviruses encoding most of the same proteins, including 
Gag, Pol, and Env, as well as accessory proteins Tat, Rev, Nef, Vif, and Vpr. HIV-1 encodes 
Vpu while SIVmac, like the SIVsm lineage it was derived from, encodes Vpx 154. Both HIV and 
SIV use CD4 as a primary entry receptor with CCR5 as the primary coreceptor 29,155. Their 
replication cycles are similar, and they use many of the same host proteins to replicate. For 
example, the preference for integration in actively transcribed genomic regions without 
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preference for CpG islands or transcription start sites is the same in HIV-1 and SIV 156. The 
differences in accessory proteins often stem from adaptation to their host species 109.  
 HIV-1 originated in humans as cross-species transmission events from chimpanzee SIV 
157. Each HIV-1 lineage, termed groups M, N, O, and P, are derived from an individual 
transmission event from SIVcpz (groups M and N) or SIVgor 158. Similarly, SIV in rhesus 
macaques (SIVmac) arose as a cross-species transmission in United States primate centers from 
SIV in sooty mangabys (SIVsm) 159. Natural host species for SIV generally fail to progress to 
AIDS despite active viral replication 160. HIV-1 and SIVmac generally do cause AIDS in their 
hosts, a similarity underlined by their relatively recent cross-species origins. 
 SIVmac was isolated in rhesus macaques shortly after identification of HIV-1 161, and the 
similar disease course was quickly recognized 162. AIDS in both species results in generalized 
immune activation, CD4+ T cell depletion (especially from mucosal sites) 163, opportunistic 
infections, weight loss, and wasting 164. Critically, rhesus macaques and humans share a hallmark 
feature of HIV and SIV infection: the dramatic depletion of CD4+ T cells in the gut mucosa 
165,166. The loss of these cells, which are not fully reconstituted even on antiretroviral therapy 
167,168, could underlie eventual immune dysfunction.  
Advantages of the SIV and rhesus macaque system are many. Animals can be 
experimentally infected such that the time of infection is precisely known. This allows for study 
of the earliest phases of infection, at a time before most infected humans are aware of infection. 
Animals can be sacrificed, allowing access to tissue in locations and in amounts that would be 
unobtainable in humans. Experimental manipulations that worsen disease such as CD8+ T cell 
depletion during infection can be tested in macaques 169. The route and dose of infection can be 
chosen such that it either approximates most human infections using a repeated low dose 
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mucosal route 170 or ensures a reliable and synchronous infection by using a high dose 
intravenously. Additional routes of infection that also mimic human acquisition have been 
developed 164. Many years of experience with SIV and rhesus macaques have resulted in well-
known viral kinetics such that the peak of acute infection can be relatively accurately predicted 
171. Finally, the viral inoculum is known and a particular sequenced clone can be utilized, 
simplifying PCR-based viral quantification. 
 
1.F. Pathogenesis and CD4 depletion 
The classical phases of HIV infection are viral transmission and acquisition, acute/early 
infection, viral set point and clinical latency, and AIDS/NeuroAIDS (Figure 1.1). AIDS is a 
profound immunodeficiency due to loss of CD4+ T cells, classified in part by measuring fewer 
than 200 CD4+ T cells per μl of blood plasma. On average, about half of untreated HIV-positive 
persons will develop major opportunistic complications within 10 years of becoming infected 13. 
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In general, HIV infections are established by a single viral variant in sexual transmission 
or one to a few variants in intravenous drug use or mother-to-child transmission 173,174. The 
majority of transmissions are across a mucosal surface: lower intestinal tract or colorectal 
mucosa through infected body fluids and semen in sexual transmission, and upper intestinal tract 
in mother to child transmission from blood/cervical mucus during delivery or from breast milk 
175. There is an initial focus of infection in activated and resting CD4+ T cells in or near the 
epithelial layer 176,177. Dendritic cells may facilitate the initial CD4+ T cell infection but their in 
vivo relevance is not established 23,178,179. Replication then spreads to proximal lymphoid organs 
by multiple potential mechanisms including free virus diffusion, travel of infected T cells, and/or 
transport by dendritic cells 13. During the peak of acute infection, CD4+ T cells are rapidly 
 
Figure 1.2. HIV disease course 172. 
A typical course of HIV infection is displayed comparing plasma viral load and peripheral blood 
CD4+ T cell count. Experimental infection of rhesus macaques with high doses of SIV will 
progress faster with a peak of acute infection 10-14 days post infection.  
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depleted from the gut mucosa 163,165,166,180. This depletion can encompass over one half of the 
memory CD4+ T cells during the acute phase alone 165. Increased replication in lymphoid tissue 
subsequently leads to systemic infection. For example, two weeks after intravenous infection in 
rhesus macaques, SIV is found at relatively high levels in all lymphoid organs 13. During the 
course of chronic infection, inflammation, increased cell turnover, and possibly underlying 
microbial translocation are factors that contribute to the slow decline of CD4+ T cells in most 
infected persons to the point at which there is profound immunodeficiency in both T and B cell 
responses 13,181. This profound loss of CD4+ T cells results in compromised immune responses to 
infections and malignancies related to viral pathogens.  
 
 
Figure 1.3. Regions of the intestine 182. 
Though CD4+ T cells are depleted throughout the intestinal immune system by HIV and SIV, we 
focused on jejunum tissue since it is more abundant than ileum in rhesus macaques. 
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Since CD4+ T cell depletion is the primary cause of immunodeficiency, a large body of 
research has focused on mechanisms of CD4+ T cell loss. The kinetics of CD4+ T cell loss are 
too rapid to be explained by impairment of cell production, implying direct or indirect 
mechanisms of cell death. While elimination of infected CD4+ T cells by immune mechanisms 
like cytotoxic T lymphocytes (CTLs) is certainly possible, depletion of CD8 T cells did not 
change the lifespan of productively SIV infected cells in vivo, indicating a virus-driven 
mechanism 183. However, infected monocyte-derived macrophages can produce virus in vitro for 
weeks, whereas infected CD4+ T cells die in days, suggesting viral replication alone does not 
always result in killing 184. The short half-life of virus in blood after antiretroviral therapy is 
initiated suggests CD4+ T cells are killed as rapidly in vivo as in vitro 185. Possible viral 
mechanisms of CD4+ T cell destruction can be categorized as either direct or indirect. 
Various viral mechanisms have been implicated for direct viral killing of CD4+ T cells. 
Envelope protein expression alone can be toxic 186 and surface expression can lead to interaction 
with nearby cells and formation of syncytia and apoptosis 187. Membrane disruption due to 
budding 188 and accumulation of unintegrated DNA 189 have also been posited as direct 
mechanisms of CD4+ T cell death. The HIV protease can induce apoptosis through a caspase 
8/caspase 9 mechanism 190. Additional mechanisms from other viral proteins have also been 
suggested 191.  
Killing of non-productively infected bystander cells, or indirect killing, is also likely to 
play a significant role in HIV and SIV pathogenesis. The vast majority of cells undergoing 
apoptosis in lymph nodes of infected children or rhesus macaques in one study were virus-
negative 192. By in situ hybridization for SIV RNA, the total number of cells infected and lost 
from days 6 to 28 after inoculation could account for only 20% of the total observed CD4+ T cell 
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depletion 180. Many potential mechanisms exist for bystander killing, such as activation-induced 
cell death, immune activation increasing Fas and Fas-ligand expression on T cells, through TNF 
or TRAIL-mediated pathways, or through soluble viral proteins 191. More recently, evidence for 
abortive infection, entry without successful completion of the viral replication cycle, leading to 
killing of apparent bystander cells through a caspase-3 and -1 mechanism, has been proposed in 
tonsil tissue, though primarily in the setting of CXCR4-tropic virus 193. 
 
1.G. Immune responses to HIV and SIV 
Innate Immunity 
 The innate immune response is the first line of defense against infection, able to respond 
in a non-antigen specific manner before adaptive immune responses develop. Cellular 
components of innate immunity include Langerhans cells, dendritic cells, monocytes, 
macrophages, natural killer cells, and γδ cells that initially have effector functions 194. Later in an 
immune response, innate immune responses may act to support or shape adaptive immunity. 
Innate immune responses are typically initiated when innate immune cells sense pathogen 
associated molecular patterns (PAMPs) or damage associated molecular patterns (DAMPs) with 
pattern recognition receptors (PRRs). The PRRs sensing HIV have long been debated. Proposed 
PRRs include TRIM5 sensing capsid in T cells 124, cGAS sensing reverse transcription 
intermediates 195, IFI16 sensing viral DNA in T cells 196, TLR7 sensing viral RNA in 
plasmacytoid dendritic cells 197, and tetherin in a virion-producing cell 198. Production of non-
cellular components including interferons, chemokines, the complement system, and defensins 
are consequences of PRR signaling. Restriction factors are also a component of intrinsic innate 
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immunity since they are capable of acting immediately and their expression is often linked to the 
innate immune response 92.  
 Acute HIV infection results in a cytokine storm in which IFN-α, IL-15, TNF-α, and IP-10 
are rapidly induced in the first week of infection. Other proinflammatory cytokines/chemokines 
appear around 7-9 days post-infection, and a more sustained elevation of immunoregulatory 
cytokines such as IL-10 occurs at later time points 199. The secretion of MIP-1α (CCL3), MIP-1β 
(CCL4), and RANTES (CCL5) can prevent SIV infection by binding to and downmodulating the 
CCR5 coreceptor 200,201. Interferon production can induce a protective antiviral state, and HIV 
has long been known to be interferon sensitive both in vitro 202 and in vivo 203, though a complete 
understanding of the mechanism of interferon-induced protection is complicated by the large 
number of induced interferon-stimulated genes. 
Innate immune responses to HIV may have both protective and pathogenic consequences. 
During the initial stages of infection with a small focus of infection, recruitment and activation of 
additional susceptible cells with proinflammatory signals could allow infection to spread 204-206. 
Another clear example is the association between certain NK cell receptors (KIRs) and their 
corresponding MHC ligands, where certain combinations or copy number variations have been 
shown to be associated with lower viral loads while others are linked to higher viral loads 207,208.   
 Macrophages have important functions in tissue immunity and repair, antigen 
presentation, and tissue homeostasis 209. While macrophages themselves are not antigen-specific, 
they can direct epithelial cell maintenance, tissue remodeling, and recruitment of other 
leukocytes through the production of cytokines and chemokines 209. However, macrophages are 
another component of the innate immune system with both protective and pathogenic roles in 
HIV/SIV infection. Macrophages can contribute to systemic and chronic inflammation, which is 
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the best predictor of the rate of HIV/SIV disease progression 210. This inflammatory contribution 
is thought to occur by multiple mechanisms, including direct infection of macrophages by 
HIV/SIV, a response to microbial products translocated from the GI tract lumen, phagocytosis of 
infected CD4+ T cells or antibody complexes, and others. 
T cell response 
 In general, the adaptive immune response to HIV in humans and SIV in macaques is 
likely a case of too little and/or too late because it fails to prevent systemic spread or to clear the 
infection 211. Nevertheless, it is clear that the T cell response does play a role in both acute and 
chronic infection. Early studies showed cytotoxic lymphocyte-mediated pressure on viral 
sequences 212 and that the CD8+ T cell response associates with the decline in viremia after acute 
infection 213,214. The expression of certain class I HLA alleles strongly associates with disease 
outcome 215,216, and experimental depletion of CD8+ T cells in macaques demonstrated a key 
role of this cell population in viral control 169,217. Additionally, viral evolution at sites of CTL 
recognition can be detected during peak viremia 218. 
Naïve T cells are quiescent, requiring antigen stimulation to become activated 219. Once 
activated, CD8+ T cells can function in multiple ways, including direct lysis of virus-infected 
cells as well as production of cytokines and chemokines such as IFN-γ, IL-2, TNF-α, CCL3, 
CCL4, CCL5, and others. Debate still exists regarding the relative importance of lytic or 
cytokine producing mechanisms for control of HIV infection by CD8+ T cells. Rapid viral 
sequence evolution during acute HIV infection suggests lysis of infected cells is a predominant 
mechanism 218. However, depletion of CD8+ T cells after viral set point has been achieved did 
not result in changes of the lifespan of infected cells, suggesting alternative mechanisms of viral 
suppression 183,220. 
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The earliest detectable CD8+ T cell responses to HIV in peripheral blood are narrowly 
directed to only a few epitopes, predominantly in Env and Nef 218. These responses are likely 
functional, since viral evolution at sites of CTL recognition has been detected as early as peak 
viremia 218. Interestingly, HIV-specific CD8+ T cell responses in lymph nodes have been shown 
to be significantly higher than in peripheral blood during chronic infection 221, and very little is 
known about responses in tissue during acute infection 222. As infection progresses, the breadth 
of HIV-specific CD8+ responses increases 223, and the average person targets at least 14 epitopes 
during chronic infection 224. A lower viral load is associated with a broader Gag response 225 and 
polyfunctional T cells exhibiting both cytolytic and cytokine-producing qualities 226. Elite 
control, maintenance of a low viral load without treatment, is significantly associated with SNPs 
in the HLA region 227 and HLA alleles 215,216, emphasizing the importance of the T cell response 
in chronic infection. 
HIV clearly elicits CD4+ T cell responses as well, but these responses generally occur at 
significantly lower frequencies than CD8+ T cell responses. This is due in part to the dramatic 
depletion of CD4+ T cells early in infection 228. HIV-specific CD4+ T cell responses are detected 
at higher frequencies around the time of peak viremia and are then rapidly lost 229. CD4+ T cells 
are important for maintaining CD8 T cell responses. For example, lack of CD4+ T cells in mice 
significantly impairs CD8+ T cells 230. Without appropriate CD4+ T cell help, antigen-stimulated 
CD8+ T cells expand rapidly, become exhausted, and exhibit impaired generation of long-term 
memory populations, a process requiring IL-2 231. The lack or impairment of CD4+ T cell help 
may be the cause of large magnitude (up to 19% of CD8+ T cells can be HIV-specific 232) but 
poorly functional CD8+ T cell response that fails to clear infection. 
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B cell and antibody response 
 Similar to the T cell response, the antibody response to HIV is too little and/or too late to 
prevent systemic establishment or clear infection, and again antibody responses likely play a role 
in modulating the outcome of infection. Antibodies can function in two general ways: by binding 
free virions and blocking their binding or entry into cells (neutralization), or by non-neutralizing 
mechanisms. Non-neutralizing mechanism include virion aggregation; blocking virion 
transcytosis across epithelial cells; and by binding antigen on an infected cell and interacting 
with Fc receptors of effector cells, for example phagocytes (Ab-mediated cellular phagocytosis) 
or natural killer cells (Ab-dependent cellular cytoxicity) 233.  
The first detectable B cell response in HIV infection is in the form of immune complexes 
that develop about a week after detectable viremia 234. Approximately a week later, free plasma 
anti-HIV antibody to gp41 appears and is followed about two weeks later by anti-gp120 
antibodies 234. These binding antibodies do not appear to impact the early plasma viral load 234 or 
exert selective immune pressure 173. Neutralizing antibodies (NAbs) appear months later, and 
these can drive neutralization escape 235. NAbs generally increase in potency over time, and in 
approximately 30% of individuals antibodies capable of recognizing heterologous virus variants, 
termed broadly cross neutralizing (BCN) antibodies, eventually develop. Levels of viremia and 
length of time infected (generally multiple years) seem to be associated with BCN antibody 
development 236. Many of the monoclonal BCN antibodies that have been isolated have features 
such as high levels of hypermutation, suggesting they have undergone multiple rounds of affinity 
maturation 237. This observation suggests that, in addition to long-term antigen exposure, 
functional B cell help in germinal centers where antibody evolution occurs may be critical to 
effective antibody development.  
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 There is significant interest in antibody-based approaches for HIV vaccine development 
since protection induced by most vaccines correlates with antibody responses 238,239. Importantly, 
pre-existing antibody responses could prevent infection establishment. Additionally, in non-
human primates there is significant evidence that passive infusion with high levels of 
neutralizing antibodies can block infection 240-242 and that more physiologically relevant antibody 
levels can increase the number of viral challenges needed to infect 243, providing proof-of-
principle evidence. Moreover, the only human HIV vaccine trial to date with a signal of efficacy, 
RV144, appears to have afforded protection by induction of non-neutralizing V2-specific 
antibodies 244,245. Finally, as with T cell responses, HIV-specific antibody responses at mucosal 
sites are poorly understood yet could be critical to effective vaccine protection 246. 
 
1.H. T follicular helper cell biology 
 T follicular helper (Tfh) cells are a specific subset of CD4+ T cells that is able to provide 
help to B cells, thereby supporting the induction of antibody responses 152. Tfh development is a 
multistage and multisignal process with significant heterogeneity. Accordingly, there is no single 
event that delineates Tfh differentiation. Multiple redundant signals and pathways for Tfh 
development are likely to exist, so the following developmental scenario represents a general 
process that may not apply to all situations. There is an initial priming of a naïve CD4+ T cell by 
recognition of cognate antigen on a dendritic cell (DC) 247. Depending on a combination of 
signals from the DC, including IL-6, ICOS, and the T cell receptor (TCR) strength or dwell time, 
and the lack of IL-2, the CD4+ T cell undergoes a cell-fate decision within the first few rounds 
of replication 248-252.  
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If CXCR5 is expressed, the CD4+ T cell will migrate to the border (interfollicular zone) 
of the B cell follicle and interact with antigen-specific B cells. This migration is aided by a 
number of factors: the downregulation of CCR7, a chemotactic receptor for the T cell zone; 
downregulation of P-selectin glycoprotein ligand 1 (PSGL1); and ICOS-ICOS-ligand binding, 
(in addition to its function as a costimulatory molecule, can also induce migration of CD4+ T 
cells) 152,253. B cells are generally required for development of Tfh cells 254. B cells serve as the 
main antigen presenting cells (APCs) in lymph nodes since mature dendritic cells die in a few 
days during acute infection or immunization. APCs are critical as antigen-specific CD4+ T cells 
require antigen recognition for each cell division, unlike antigen-specific CD8+ T cells 249.  
The third stage of differentiation occurs in the germinal center (GC), a distinct region of 
the lymph node consisting of stroma, macrophages, follicular dendritic cells, GC B cells, and Tfh 
cells. Here further interaction with B cells leads to the mature GC Tfh phenotype, which is well 
conserved across different conditions and species: CXCR5high, PD1high, Bcl6high, Mafhigh, SAPhigh, 
PSGL1low, CD200+, BTLAhigh, and CCR7low 152. 
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Transcription factors important for Tfh differentiation include Maf, IRF4, BATF, STATs, 
E proteins, and the lineage-defining transcription factor BCL6. BCL6 expression likely promotes 
Tfh differentiation by multiple mechanisms that have not been fully described. It is known, 
however, to repress Blimp-1 256 as well as repress Th1, Th2, Th17, and Treg transcription factors 
and cytokine genes 251,257. 
Tfh cells are required for germinal center formation and function, their primary role in 
the immune response. Tfh cells regulate GC size 258, support high affinity B cell entry into GCs 
 
Figure 1.4. Tfh cell generation 255. 
Diagrammatic representation of the Tfh development pathway from naïve CD4+ T cells to 
germinal center Tfh cells. (Reprinted with permission from Nurieva et al., 2010 255)   
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259, and select high affinity B cells 260. GCs are the main sites for antigen-activated B cell clones 
to undergo expansion, immunoglobulin gene hypermutation and selection, and affinity 
maturation. GC B cell selection results in multiple potential outcomes: continued expansion and 
evolution, apoptosis, or exit from the GC with differentiation into memory B cells or plasma 
cells 261. Tfh cells recognizing peptide:MHC complexes on B cells in the light zone of germinal 
centers provide help signals to GC B cells essential for B cell survival and increased 
proliferation. GC B cells migrate to the dark zone, proliferate, undergo somatic hypermutation, 
and migrate back to the light zone to re-present antigen to Tfh cells, at which point the highest 
affinity B cells (those that bound and endocytosed the most antigen) are selected to undergo 
another round of proliferation and mutation 152.  
The nature of the help signals provided by Tfh cells to GC B cells is still under 
investigation. CD40L and several canonical secreted molecules of Tfh cells (CXCL13, IL-21, 
and IL-4) are all involved. Tfh cells are regulated to reduce their own proliferation despite 
exposure to peptide:MHC complexes. Regulation may be achieved by control of pathways 
downstream of TCR signaling, high levels of PD-1 expression, and a subset of Tfh cells 
expressing Foxp3 termed Tfh regulatory cells 262. 
 Tfh cells have been implicated in multiple aspects of HIV immune response as well as 
pathogenesis. As their primary role is supporting B cell development and affinity maturation, Tfh 
cells have been associated with HIV-specific B cell responses, importantly including broadly 
neutralizing antibodies that generally require extensive hypermutation 263,264. Tfh cells are also 
target cells for HIV and SIV infection 265. It is well established that follicles are major sites of 
HIV 266-269 and SIV 266,270 replication. One mechanism of enhanced follicular virus replication 
could be the lack of CD8+ cytotoxic lymphocytes (CTLs) in follicles, as this concentrated 
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replication does not exist in acute infection prior to the CTL response 270 or after CD8 depletion 
271. Although Tfh cells are depleted in the spleen during acute SIV infection 272, they appear to 
accumulate in blood 273 and lymph nodes 274 later in infection and could contribute to 
dysregulated antibody production. Tfh cells have also been suggested as significant part of the 
latent viral reservoir in both elite controller rhesus macaques and treated aviremic humans 271,275. 
Finally, loss of Tfh regulatory cells has been implicated in accumulation of Tfh cells and 
immune activation in chronic SIV infection 276. 
 
1.I. Single cell gene expression 
Widely used methods to measure gene expression such as microarrays and quantitative 
real-time PCR (qRT-PCR) generally analyze relatively large numbers of cells (106 or more). 
Analysis of gene expression in these studies therefore reflects an average of all the cells in the 
sampled population. Since cell populations are not homogenous, measurements that average 
expression over multiple cells can obscure differences among subpopulations. For example, stem 
cells may make up a vanishingly small proportion of a bulk cell sample yet are critically 
important to tissue generation 277. 
 Gene expression on a single cell level is variable such that even housekeeping genes in 
genetically and cell surface phenotypic marker-identical cells have a broad range of gene 
expression values 278. This variability can be due to the intrinsic stochastic nature of biochemical 
processes regulated by a small number of molecules as well as extrinsic sources such as the cell 
cycle and the unique signals from the local microenvironment 277,279. Transcription and 
translation on the single cell level occurs in periodic bursts 280,281, meaning genes are not 
expressed uniformly in every cell or at every time. To account for stochastic differences at the 
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single cell level, many cells and many genes need to be analyzed in order to achieve reliable 
discrimination of subpopulations. Single cell measurements can deconvolute cell types in 
putatively homogenous populations, discovering the identity and gene expression profiles of 
subpopulations, even if they are rare 278.  
Early single cell gene expression measurements were limited in the number of cells or 
genes that could be analyzed 282. Recent advances in microfluidic devices have allowed 
significant increases in the throughput in both the number of cells and genes that can be analyzed 
by single cell qRT-PCR. The Fluidigm C1 Single Cell Auto Prep system allows a suspension of 
approximately 2000-5000 cells to flow through a microfluidic integrated fluidic circuit (IFC) 
with 96 single cell capture sites. Once cells are captured and visualized, this system then lyses 
them, performs reverse transcription, gene-specific pre-amplification, and produces cDNA for 
each captured cell. Output cDNA is then loaded into a Fluidigm BioMark IFC for qRT-PCR of 
96 assays from each captured cell. 
 
 
 
Figure 1.5. Schematic outlining single cell isolation and gene expression analysis procedure. 
The C1 Single-Cell Auto Prep system is used to perform single cell isolation steps and the 
BioMark system is used to perform qRT-PCR of up to 96 genes in 96 cells (A). The integrated 
fluidic circuit (IFC) is a standard sized plate with a microfluidic array at the center (B). The 
callout shows one of 96 cell capture sites contained in one C1 IFC. 
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1.J. Scope of the Dissertation 
It is known that differences in CD4+ T cell susceptibility to SIV infection exist based on 
the memory subset 283,284 and the tissue location of the cells 163,165,180. Very little information 
exists on the expression of restriction and dependency factor genes in primary cells. Previous 
studies attempting to comprehensively measure expression of a panel of restriction factor genes 
285,286 failed to account for possible differences among memory subsets of CD4+ T cells and only 
analyzed cells from peripheral blood, not the highly susceptible cells from intestinal mucosa.
  In Chapter 2, we hypothesized that comprehensive analysis of expression of confirmed 
and putative host dependency factors and restriction factors would define a molecular signature 
of CD4+ T cells most susceptible to infection by SIV. Expression of 45 confirmed and putative 
restriction factors and 40 dependency factors were analyzed in primary CD4+ T cell memory 
subsets from peripheral blood and jejunum in both uninfected and acutely SIV infected rhesus 
macaques.  
 Gene expression at the single cell level can differ from that seen in bulk measurements of 
thousands of cells 277,278. No study has measured single cell gene expression in cells from 
intestinal CD4+ T cells, with or without viral infection. In Chapter 3, we hypothesized that 
comprehensive analysis of expression of host dependency factors and restriction factors on a 
single-cell basis would define a molecular signature of CD4+ T cells susceptible to infection by 
SIV, revealing a novel subpopulation not identified based on surface phenotype. Over 300 single 
memory CD4+ T cells from acutely SIV infected rhesus macaque jejunum were analyzed for 
their expression of 96 genes and SIV transcripts. Individual infected and uninfected cells were 
identified, and a novel subpopulation of PD-1 and CXCR5 expressing cells were identified as 
highly SIV susceptible.
  
Chapter 2: Dynamic modulation of expression of lentiviral restriction factors in primary 
CD4+ T cells following SIV infection 
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2.A. Abstract 
Although multiple restriction factors have been shown to inhibit HIV/SIV replication and 
multiple genes have been identified as necessary for viral replication, termed dependency factors, 
little is known about their expression in vivo. Expression of 45 confirmed and putative HIV/SIV 
restriction factors and 40 putative dependency factors was analyzed in CD4+ T cells from 
peripheral blood and jejunum in rhesus macaques, revealing distinct expression patterns in naïve 
and memory subsets. In both peripheral blood and jejunum, memory CD4+ T cells expressed 
higher levels of multiple restriction and dependency factors compared with naïve cells. However, 
relative to their expression in peripheral blood CD4+ T cells, jejunal CCR5+ CD4+ T cells 
exhibited significantly lower expression of multiple restriction factors, including APOBEC3G, 
MX2, and TRIM25, which may contribute to the exquisite susceptibility of these cells to SIV 
infection. In vitro stimulation with anti-CD3/CD28 antibodies or type I interferon resulted in 
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upregulation of distinct subsets of multiple restriction factors. After infection of rhesus macaques 
with SIVMAC239, expression of most restriction factors substantially increased in all CD4+ T cell 
memory subsets at the peak of acute infection. Jejunal CCR5+ CD4+ T cells exhibited the 
highest levels of SIV RNA, corresponding to the lower restriction factor expression in this subset 
relative to peripheral blood prior to infection. These results illustrate the dynamic modulation of 
restriction factor expression by memory differentiation, stimulation, tissue microenvironment 
and SIV infection, and suggest that differential expression of restriction and dependency factors 
may play a key role in modulating the susceptibility of different populations of CD4+ T cells to 
lentiviral infection. 
 
2.B. Introduction 
 Restriction factors serve as a key host defense against virus infection. Many of these 
genes have well-described activity against the primate lentiviruses HIV and SIV, including the 
APOBEC3 DNA deaminase family, the TRIM family, BST-2/Tetherin, and SAMHD1 92. In 
addition to the more well-studied restriction factors, screens have been performed to identify 
additional restriction factors. A whole genome siRNA screen has identified putative restriction 
factors such as the PAF1 complex and exosome components 119. A screen for genes sharing 
genomic characteristics of known restriction factors identified APOL and TNFRSF family 
members and used cell-based assays to confirm restriction of HIV-1 287. While many studies 
focus on the impact of a single factor, the total effect of restriction factors on virus infection is 
likely to be cumulative. Though much work has focused on defining mechanisms of action and 
structure/function studies for individual restriction factors, little is known about the levels of 
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expression in primary CD4+ T cells and how expression may be modulated as a result of T cell 
differentiation and activation or during the course of acute lentiviral infection.    
Retroviruses have complex lifecycles, yet only encode a small number of proteins and are 
therefore reliant on many cellular proteins to complete their replicative cycle. Some host proteins 
that facilitate different steps of the retroviral lifecycle (termed “dependency factors”) have been 
well-studied while others have only been identified in screens with little further study to date. 
Similar to restriction factors, a combination of well-studied published genes such as RANBP2 54, 
NUP153 55, and putative dependency factors found in screens 15-18,21 have been identified. Also 
similar to restriction factors, the effect of dependency factor expression on viral replication is 
likely to be cumulative, as they affect distinct steps in the viral replication cycle.  
Naïve CD4+ T cells that are stimulated by cognate antigen can differentiate into a broad 
range of functionally specialized cell subsets 288. Studies have found that the differentiation 
status of a CD4+ T cell influences its susceptibility to HIV and SIV infection, and specifically 
that memory CD4+ T cells are more likely to be infected than naïve CD4+ T cells 283,284. The 
effects of memory differentiation on restriction and dependency factor expression are 
incompletely understood and may contribute to the differential susceptibility of memory and 
naïve cells.   
During acute infection, HIV and SIV primarily replicate in and deplete gut CD4+ T cells 
163,165,180; however, primary cells from mucosal tissues are relatively understudied as compared to 
cells from peripheral blood due to the difficulty in obtaining tissue samples 289. Whether 
expression of restriction or dependency factors differs between peripheral blood cells, which are 
infected at lower rates, and cells in the mucosa is currently unknown.  
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The events of acute immunodeficiency virus infection are challenging to study in 
humans. Analysis of acute lentiviral infection in nonhuman primates has multiple advantages, 
including the ability to control the inoculating strain, the precise timing of sampling, and superior 
access to mucosal and lymphoid tissues. In light of strong evidence documenting the induction of 
interferon during primary SIV and HIV infection and the fact that many restriction factors are 
known to be interferon-stimulated genes 206,290, we reasoned that expression of restriction factors 
is likely to be modulated during the course of SIV infection. However, data on the modulation of 
expression of restriction factors in different CD4+ T cell subsets during acute SIV infection, 
especially for the critical CD4+ target cells in the gut mucosa, is not currently defined. 
We hypothesized that the comprehensive analysis of expression of a large panel of 
confirmed and putative restriction and dependency factors would provide insights into the 
molecular mechanisms that underlie differences between naïve and memory cells in their 
susceptibility to lentiviral infection as well as the differential infectivity between peripheral 
blood and gut mucosa CD4+ T cells. Expression analysis of restriction and dependency factors 
was performed using a high-throughput microfluidic RT-PCR platform that allows for highly 
quantitative and specific analysis of up to 96 genes at a time from each of 96 samples. Using 
highly purified sorted populations of CD4+ T cells, we observed both up and down regulation of 
restriction and dependency factors due to memory differentiation that occurred in a similar 
pattern in both peripheral blood and jejunum cells. Stimulation with either anti-CD3/CD28 or 
type I interferon also altered expression of restriction factors in primary cells. Despite broad 
similarities in expression patterns between peripheral blood and jejunum, the transitional 
memory CD4+ T cells from jejunum had lower total expression of restriction factors relative to 
the same subset in peripheral blood. After infection with SIVMAC239, the transitional memory 
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CD4+ T cells from jejunum exhibited the highest level of infection. Strikingly, expression of 
most restriction factors increased in acute SIV infection in all memory subsets.  
 
2.C. Materials and Methods 
Animals 
The eight Indian-origin rhesus macaque monkeys (Macaca mulatta) described in this study 
were housed at the New England Primate Research Center (NEPRC) in accordance with the 
regulations of the American Association of Accreditation of Laboratory Animal Care and the 
standards of the Association for Assessment and Accreditation of Laboratory Animal Care 
International.  All protocols and procedures were approved by the relevant Institutional Animal 
Care and Use Committee. Care met the guidance of the Animal Welfare Regulations, OLAW 
reporting, and the standards set forth in The Guide for the Care and Use of Laboratory Animals 
291.  
Infection of four animals was performed intravenously with a 500 50% tissue culture 
infective dose (TCID50) of SIVmac239 (generously provided by Francois Villinger (Emory 
University)). This ensured a reliable and synchronous infection with a well-studied disease 
course. Euthanasia took place at ten days post-infection using protocols consistent with the 
American Veterinary Medical Association (AVMA) guidelines. 
 
Lymphocyte isolation 
Peripheral blood samples were collected from unvaccinated healthy rhesus macaques for 
purification of CD4+ T cells. Blood was collected in EDTA vacutainer tubes (Becton Dickinson 
Vacutainer systems, Franklin Lakes, NJ), and peripheral blood mononuclear cells (PBMC) were 
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separated by density gradient centrifugation (Lymphocyte Separation Medium; MP Biomedicals 
Inc., Solon, OH). Jejunum tissue was isolated at time of euthanasia, washed with PBS, separated 
into small pieces with a scalpel, incubated with 5 mM EDTA for 30 min, washed, and incubated 
with 15 U/ml type II collagenase (Sigma-Aldrich) followed by mechanical disruption with an 18 
gauge-feeding needle and filtration through 70 μm cell strainers (BD Biosciences). Lymphocytes 
were then enriched by bilayer (35%/60%) isotonic Percoll density gradient centrifugation (1000 
× g, 20 min) and the interface containing the lymphocytes was collected 292. 
 
Antibodies and cell sorting 
To purify naïve and memory phenotypes, PBMC were stained with CD3 (SP34)-Pacific 
Blue; CD4 (L200)-FITC; CD8 (RPA-T8)-Alexa 700; CD28 (28.2)-ECD (Beckman Coulter), 
CD95 (DX2)-APC, CCR5 (3A9)-PE, and CCR7 (2D12)-PE-Cy7. Antibodies were obtained from 
BD Pharmingen unless specified. PBMCs were initially labeled with LIVE/DEAD viability stain 
(Life Technologies) and washed, incubated with the CCR7 antibody for 15 min at 37°C, then 
incubated with all other antibodies for 20 min at room temperature and washed prior to sorting. 
Cell sorting was performed using a FACS Aria II cell sorter (BD Biosciences). Sorted cell 
populations were > 99% pure. 
 
In vitro cell stimulation 
CD4+ T cell enrichment prior to stimulation with αCD3/αCD28 or interferon was 
performed using the CD4+ T cell non-human primate isolation kit (Miltenyi Biotec). As verified 
by flow cytometry, purity was > 95%. For anti-CD3/CD28 stimulation, αCD3/αCD28 beads 
were generated by coupling αCD3 (FN-18) and αCD28 (L293) antibodies with Dynabeads M-
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450 Tosylactivated (ThermoFischer Scientific) in a 1:1 ratio as per manufacturer’s instructions. 
Beads were added to cells in a 3:1 ratio for stimulation. For interferon stimulation, recombinant 
human interferon-αA/D (Sigma-Aldrich) was added to cultures of freshly isolated and enriched 
CD4+ T cells at a concentration of 1000 units/mL. In both stimulation experiments, paired 
samples of unstimulated cells were used as controls. 
 
Gene expression analysis 
Real-time PCR assays specific for the indicated rhesus macaque genes were purchased 
from Applied Biosystems (ABI) (Table 1). When not available, macaque-specific custom assays 
with FAM-MGB probes were designed using Primer Express 3.0 (ABI). Sequences for custom 
assays were: APOBEC3D F-TCCCTGCACTGCAAGCTAAA,  
R-TGTGTGTGGATACATTGCCTTCA, P-AGATTCTCAGAAACCC; APOL1  
F-CTGGAGGCATCTTGCTTGTG, R-TCTTGCAAGTGCTTTGACTCGTA,  
P-ATGTGGTCAGCCTTGT; APOL6 F-AGGCAGAGGAAGAAAGTGAAGCT,  
R-TCGTCTTCACACAGAGGAACATCT, P-TTGGTTTGGAAAGGGATGAG; HERC5  
F-GGACATACAGATTATGATTGGAAAACA, R-TCACTATGGTGGGATGTGAACTG,  
P-TTGAAAAGAATGCACGTTATG; IFITM3A F-GGCCAGCCTCCCAACTATG,  
R-GGGCGCCCCCATCAT, P-AAGAGCACGATGTGGC; IFITM3B  
F-AAACCGTCTTCCCTCCTGTCA, R-GCTACCTCATGCTCTTCCTTGAG,  
P-CCCCCCAGCTATGAG; SLFN14 F-GAGGGTCTGCAACGACATTTG,  
R-GCTTCTTACAGAGGGATTCTGGTT, P-TTCCAGTGACACAGCAA; TRIM14  
F-CAGCCAGGAGCCTGATCCT, R-CCGCTGCATCTCCTGCTT,  
P-AGAGGCTTCAGGCATACA; TRIM32 F-GGCCTCAATCTGGAGAATCG,  
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R-AACCAATGGAAAAGCCACCTT, P-CAGAATGAGCACCACCTG. 
Dependency factor custom assay sequences were: PIP5K1C  
F- TGCACATTGGCATCATTGATATC, R- CCAGGTGTGCTCCAGCTTCT,  
P- CAATCCTACAGGTTCATC; SPG7 F- AGAAGAATAAGGAGAAGGATAAGTCGAA,  
R- GCCGCTCTCGGTACATCTG, P- ACGAAGAGGATAGGAGACGT; TREX1  
F- AGAGTGTGCAGCAAAGTCACTACTG, R- AGCCCATGGTTGGGTAGGA,  
P- CTGCTACGGCTCAGC; UBASH3A F- GAAGCCAGCAGCAGATGCA,  
R- CCACCAGCACGCTCTTCCT, P- CCTTGCAGGCCACCG 
 Primer sequences for the SIV gag custom assay were:  
F-GUCUGCGUCAUCUGGUGCAUUC, R-CAAAACAGAUAGUGCAGAGACACCUAGUG, 
P- CGCAGAAGAGAAAGUGAAACACACUGAGGAAG. 
All assays were confirmed to exhibit linear amplification in an eight point, three-fold 
dilution series of rhesus PBMC cDNA.  
Sorted cells were immediately frozen at -80°C in RNA extraction buffer. RNA extraction 
was performed on thawed samples using a Qiagen RNeasy Plus Micro kit, RNA purity was 
confirmed using an Agilent RNA 6000 Pico Bioanalyzer kit, and conversion to cDNA was 
performed using ABI High Capacity RT with random hexamer primers. cDNA samples were 
diluted to 200 cell equivalents, linearly pre-amplified with gene-specific primers using an ABI 
Preamp Master Mix kit and pooled TaqMan assays, and analyzed on a Fluidigm BioMark 
microfluidic real-time PCR system using 96.96 dynamic arrays. This system allows for the 
simultaneous measurement of up to 96 assays in 96 different cDNA samples. Initial calculations 
of cycle thresholds (Ct) were performed using the Fluidigm BioMark software version 4.1.3, and 
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further analysis was carried out using GenEx software version 6 (MultiD Analyses, URL: 
http://www.multid.se).   
 For SIV RT-PCR quantification, an eight-point five-fold standard curve was constructed 
of in vitro transcribed SIVMAC239 gag RNA and used to interpolate the number of gag RNA 
copies in each cell sample. Copies per cell were calculated based on the number of cells in the 
reaction. 
 
Statistical analysis 
Statistics and graphing were performed using GraphPad Prism version 6.05 for Windows 
(GraphPad Software, La Jolla California) or R 293. Naïve and memory CD4+ T cell restriction 
factor expression was compared using repeated measures ANOVA with Benjamini Hochberg 
correction for multiple comparisons. All multiple comparison corrections are an extension of the 
Benjamini Hochberg method 294 updated by Storey 295 and implemented in the R package limma 
296. PCA was performed using R and the function hclust {stats} 293 with resulting axis 
coordinates and loading factors visualized in GraphPad Prism. Peripheral blood and jejunum 
memory subsets were compared using two-way ANOVA with Benjamini Hochberg correction. 
Aggregate peripheral blood and jejunum expression differences were assessed with a paired 
Student’s t-test. Pre- and post-infection differences were assessed using a two-way ANOVA with 
Benjamini Hochberg correction. 
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2.D. Results 
Restriction factor expression in peripheral blood CD4+ T cells 
As a comprehensive approach to analyzing the expression of restriction factors in primary 
CD4+ T cells, a list of confirmed or putative HIV/SIV restriction factors (Table 2.1) and 
dependency factors (Table 2.2) was compiled from published sources. To assess expression of 
restriction and dependency factors in defined cell populations in macaques not infected with SIV, 
PBMCs and jejunum lymphocytes were isolated from four Indian-origin rhesus macaques, 
stained with monoclonal antibodies, and sorted into four highly purified populations: naïve 
(CD3+4+28+95-CCR7+CCR5-), central memory (CD3+4+28+95+CCR7+CCR5-), transitional 
memory (CD3+4+28+95+CCR7-CCR5+), and effector memory (CD3+4+28-95+CCR7-CCR5-) 
297,298. RNA was extracted and the cDNA samples were analyzed on the Fluidigm BioMark 
microfluidic real-time PCR system. 
Table 2.1. List of restriction factor genes selected for expression analysis. 
Assay ID numbers are provided for the ABI TaqMan assays. Sequences for the custom assays 
are provided in the text. 
Gene 
Name 
ENTREZ 
ID Mm 
ENTREZ 
ID 
human 
HGNC Full Name Assay ID Reference 
APOBEC3A 702708 200315 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3A Rh04329459_m1 
299,300 
APOBEC3C 705870 27350 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C Rh03418653_s1 
299 
APOBEC3D 705996 140564 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D Custom 
116,299 
APOBEC3F 723812 200316 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F Rh04256581_s1 
116,299 
APOBEC3G 574398 60489 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G Rh02788475_m1 
115,116,
299 
APOBEC3H 723811 164668 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H Rh04256315_m1 
116,299 
APOL1 694508 8542 apolipoprotein L, 1; APOL; APO-L; FSGS4; APOL-I Custom 95,301 
APOL6 693593 80830 apolipoprotein L, 6 Custom 
95,287 
302  
BST2 719092 684 CD317; NPC-A-7; bone marrow stromal cell antigen 2; Tetherin Rh02848328_m1 
143,144 
CD164 699242 8763 CD164 molecule, sialomucin Rh02859344_m1 287 
CDKN1A 719199 1026 cyclin-dependent kinase inhibitor 1A (p21, Cip1) Hs00355782_m1 302,303 
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Table 2.1. (Continued) 
Gene 
Name 
ENTREZ 
ID Mm 
ENTREZ 
ID 
human 
HGNC Full Name Assay ID Reference 
CTR9 705748 9646 Ctr9, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) Rh02792191_m1 
119 
EXOSC10 714153 5394 exosome component 10 Rh00897424_m1 119 
EXOSC2 715960 23404 exosome component 2 Rh02930061_mH 119 
EXOSC3 716347 51010 exosome component 3 Rh02830694_m1 119 
GSN 699705 2934 gelsolin (amyloidosis, Finnish type) Rh02794823_m1 304 
HERC5 702743 51191 hect domain and RLD 5 Custom 305 
IFITM1 697687 8519 interferon induced transmembrane protein 1 (9-27) Rh02809735_gH 94 
IFITM3A 697829 10410 [predicted] interferon induced transmembrane protein 3-like Custom 
94 
IFITM3B 697564 10410 [predicted] interferon induced transmembrane protein 3-like Custom 
94 
ISG15 700141 9636 ISG15 ubiquitin-like modifier Rh02915441_g1 305 
MICB 715141 4277 MHC class I polypeptide-related sequence B Rh02787686_m1 95 
MOV10 705910 4343 Mov10, Moloney leukemia virus 10, homolog (mouse) Rh02878489_m1 306-308 
MX2 780935 4600 myxovirus (influenza virus) resistance 2 (mouse) Rh02801425_m1 131,133 
PAF1 697786 54623 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) Rh02876261_m1 
119 
PARP1 698806 142 poly (ADP-ribose) polymerase 1 Rh00911359_m1 309 
PRMT6 694284 55170 protein arginine methyltransferase 6 Rh02817860_s1 310,311 
RPRD2 - 
REAF 
715526 23248 regulation of nuclear pre-mRNA domain containing 2; REAF Rh02868968_m1 
119,120 
RTF1 706200 23168 Rtf1, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae) Rh01025583_m1 
119 
SAMHD1 709060 25939 SAM domain and HD domain 1 Rh02869977_m1 104,107 
SETDB1 716141 9869 SET domain, bifurcated 1 Rh02803155_m1 119 
SLFN11 715511 91607 schlafen family member 11 Rh02885088_m1 141 
SLFN14 718850 342618 schlafen family member 14 Custom  
TNFRSF10A 716826 8797 tumor necrosis factor receptor superfamily, member 10a Rh02846752_m1 287 
TNFRSF10D 8793 8793 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain Rh02846723_m1 
287 
TRIM14 715418 9830 tripartite motif-containing 14 Custom 95 
TRIM19 - 
PML 
700379 5371 promyelocytic leukemia Rh03043124_m1 312 
TRIM22 713814 10346 tripartite motif-containing 22 Rh02801450_m1 
129,313,
314 
TRIM25 712588 7706 tripartite motif-containing 25 Rh02856605_m1 119 
TRIM26 100141397 7726 tripartite motif-containing 26 Rh03418272_m1 127 
TRIM28 711982 10155 tripartite motif-containing 28 Rh01076235_m1 130 
TRIM32 702595 22954 tripartite motif-containing 32 Custom 315 
TRIM34 100568287 53840 TRIM6-TRIM34 readthrough transcript; tripartite motif-containing 6; tripartite motif-containing 34 Rh04256228_m1 
316 
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Table 2.1. (Continued) 
TRIM38 694861 10475 tripartite motif-containing 38 Rh02860500_m1 127 
TRIM5_3_4 574288 85363 tripartite motif containing 5; exon 3-4 junction, all isoforms Rh02788627_m1 121,317 
TRIM5A_7_
8 
574288 85363 tripartite motif containing 5; exon 7-8 junction, alpha isoform only Rh02788631_m1 
121,317 
ZC3H12A 713604 80149 zinc finger CCCH-type containing 12A; MCPIP1 Rh02882632_mH 139 
 
Table 2.2. List of dependency factor genes selected for expression analysis. 
Assay ID numbers are provided for the ABI TaqMan assays. Sequences for the custom assays 
are provided in the text. 
Gene Name ENTREZ ID Mm 
ENTREZ 
ID human HGNC Full Name Assay ID 
AKT1 697747 207 AKT serine/threonine kinase 1 Rh02834331_m1 
CCNT1 707754 904 cyclin T1 Rh02837946_m1 
CLDND1 698472 56650 claudin domain containing 1 Rh01026490_m1 
CLK2 717671 1196 CDC like kinase 2 Rh02805929_m1 
CPSF6 718331 11052 cleavage and polyadenylation specific factor 6 Rh01101216_m1 
DDX23 708185 9416 DEAD-box helicase 23 Rh01058445_g1 
DMXL1 698117 1657 Dmx like 1 Rh02857893_m1 
DNAJB2 702936 3300 DnaJ heat shock protein family (Hsp40) member B2 Rh02800276_m1 
EPAS1 714641 2034 endothelial PAS domain protein 1 Rh02838664_m1 
FNTA 712681 2339 farnesyltransferase, CAAX box, alpha Hs00954344_g1 
FYB / ADAP 693951 2533 FYN binding protein Rh02838822_m1 
GLUT1 / 
SLC2A1 698931 6513 solute carrier family 2 member 1 Rh02861051_m1 
KLF2 719492 10365 Kruppel like factor 2 Rh02927457_mH 
MAP4 NM 100423619 4134 microtubule associated protein 4; one of two possible Macaque homologs Rh02841978_m1 
MAP4 XM 711097 4134 microtubule associated protein 4; one of two possible Macaque homologs Rh02841981_m1 
MED14 699395 9282 mediator complex subunit 14 Rh02847948_m1 
MED4 704644 29079 mediator complex subunit 4 Rh02800666_m1 
MED6 693320 10001 mediator complex subunit 6 Rh02795099_m1 
NUP153 703888 9972 nucleoporin 153 Rh02856816_m1 
NUP155 706019 9631 nucleoporin 155 Rh00897468_m1 
NUP160 710968 23279 nucleoporin 160 Hs01013191_m1 
NUP85 705628 79902 nucleoporin 85 Rh02882139_m1 
PIP5K1C 721744 23396 phosphatidylinositol-4-phosphate 5-kinase type 1 gamma Custom 
PSIP1 / LEDGF 
/ P75 664733 11168 PC4 and SFRS1 interacting protein 1 Rh02851085_m1 
RAD23A 717979 5886 RAD23 homolog A, nucleotide excision repair protein Rh02803250_m1 
RANBP1 719448 5902 RAN binding protein 1 Rh00862133_g1 
RANBP2 694823 5903 RAN binding protein 2 Hs01108576_m1 
RAP1B 718171 5908 RAP1B, member of RAS oncogene family Rh02809565_g1 
RBM10 711791 8241 RNA binding motif protein 10 Rh01016429_m1 
RELA 715919 5970 RELA proto-oncogene, NF-kB subunit Rh02879402_m1 
SLC38A6 704017 145389 solute carrier family 38 member 6 Hs01553968_m1 
SPG7 699488 6687 SPG7, paraplegin matrix AAA peptidase subunit Custom 
STK39 704855 27347 serine/threonine kinase 39 Rh01085344_m1 
SUN2 704914 25777 Sad1 and UNC84 domain containing 2 Hs00992164_m1 
THOC2 697668 57187 THO complex 2 Rh01107189_m1 
TNPO3 700852 23534 transportin 3 Hs01110591_m1 
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Table 2.2. (Continued) 
Gene Name ENTREZ ID Mm 
ENTREZ 
ID human HGNC Full Name Assay ID 
TREX1 100429168 11277 three prime repair exonuclease 1 Custom 
UBASH3A 722456 53347 ubiquitin associated and SH3 domain containing A Custom 
WNK1 706493 65125 WNK lysine deficient protein kinase 1 Rh01013234_m1 
ZNRD1 712151 30834 zinc ribbon domain containing 1 Rh01548529_m1 
  
Sorting for purified populations was critical for isolating the influence of tissue location, 
since peripheral blood and mucosal tissue differ in the proportions of memory CD4+ T cell 
populations they harbor (Table 2.3). For example, jejunum CD4+ T cells were comprised of 
approximately 41% CCR5+ transitional memory (TM) T cells, while peripheral blood CD4+ T 
cells were only 9% TM phenotype. 
Table 2.3. Frequency of CD4+ T cell memory populations in jejunum and peripheral blood. 
Tissue Population Average Frequency 
Minimum 
Frequency 
Maximum 
Frequency 
Number of 
Animals 
Jejunum Naïve 24 22 29 4 
Jejunum Central Memory 26 29 47 4 
Jejunum Transitional Memory 41 43 66 4 
Jejunum Effector Memory 2 0 4 4 
      
PBMC Naïve 49 22 69 20 
PBMC Central Memory 31 70 86 20 
PBMC Transitional Memory 9 12 28 20 
PBMC Effector Memory 9 1 20 20 
 
Gene expression results from each animal were normalized by the ΔΔCt method 318 to 
both the most stable of seven endogenous control genes (POLR2A) as determined by the 
NormFinder algorithm 319 and to the naïve population (Figure 2.1.A). In general, increased 
expression was seen for many of the restriction factors in memory subsets relative to naïve cells, 
including APOBEC family members, p21, GSN, and SAMHD1. The CCR5+ transitional memory 
CD4+ T cells from peripheral blood expressed the largest number of restriction factors, 12, with 
a mean of at least four-fold greater expression relative to naïve cells. By comparison, nine 
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restriction factors were four-fold greater expressed in effector memory and six in central 
memory. 
 
Using expression data of only the restriction factor genes normalized to a stable control 
gene (POLR2A), principal component analysis (PCA) revealed expression patterns that clustered 
by memory subset (Figure 2.1.C). Since each memory subset was more similar to the respective 
subset from another animal rather than other subsets from the same animal, these data reveal a 
  
Figure 2.1. Expression of restriction factors exhibits similar patterns in peripheral blood 
and jejunum CD4+ T cell memory subsets, and is dynamically modulated by stimulation. 
Heatmap of -ΔΔCt expression values depicting memory subset expression relative to naïve for 
peripheral blood (A) and jejunum (B). Means of four animals, * = p<0.01, repeated measures 
ANOVA with Benjamini Hochberg correction. Principal component analysis for peripheral 
blood (C) and jejunum (D) based on analysis of 45 restriction factor genes. Each symbol in (C) 
and (D) represents a different animal. PC1 loading factors from the PCA for peripheral blood (E) 
and jejunum (F). 
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reproducible pattern of expression due to memory differentiation. Examination of the loading 
factors for principal component axis 1 (PC1) identified the genes driving the clustering along the 
x-axis (Figure 2.1.E). MX2, GSN, APOBEC family members, and TNFSRF family members 
were the major genes contributing to memory subset differences. These genes were among the 
most differentially expressed restriction factors among memory populations. 
 
Restriction factor expression in jejunum CD4+ T cells 
CD4+ T cells from jejunum showed a similar pattern of restriction factor expression as 
observed in peripheral blood CD4+ T cells, demonstrating that in general, restriction factor 
expression was modulated primarily by memory differentiation regardless of tissue location 
(Figure 2.1.B). Similar to peripheral blood, transitional memory cells had the largest number of 
upregulated restriction factors—eight, relative to naïve cells, as compared to four in central 
memory and five in effector memory. As in peripheral blood, PCA also clustered memory 
subsets together for jejunum CD4+ T cells, though transitional and effector memory cells were 
not as distinctly separated (Figure 2.1.D). Similar genes contributed to the spatial organization 
of samples along principal component axis 1 (PC1), including APOBECs, MX2, GSN, and 
TNFRSF genes (Figure 2.1.F).  
As TRIM5 is known to be expressed as multiple differentially spliced isoforms where 
only the α isoform is restrictive 317, we used two assays for TRIM5: one that recognizes a splice 
junction present in all TRIM5 transcripts (exon 3-4) and one that recognizes the exon 7-8 splice 
junction found only in TRIM5α. This allowed assessment of the precise functional isoform in 
case it differed in expression under the various tested conditions. In both peripheral blood and 
jejunum both TRIM5 assays showed similar patterns of expression change relative to naïve 
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CD4+ T cells, indicating the transcript levels are not differentially affected by memory 
differentiation. 
 
Dependency factor expression in peripheral blood and jejunum CD4+ T cells 
 As with restriction factors, expression of dependency factors in each memory subset was 
normalized to naïve cells and the stable control gene POLR2A using the ΔΔCt method for both 
peripheral blood (Figure 2.2.A) and jejunum (Figure 2.2.B). An average increase of expression 
in both tissue compartments was observed. Compared to restriction factors, fewer dependency 
factors exhibited significant expression modulation due to memory differentiation (17.5% in 
peripheral blood and 7.5% in jejunum compared to 46.7% and 33.3% respectively for restriction 
factors). Despite less modulation, PCA still clustered cells from the same naïve or memory 
subset tighter than cells from the same animal (Figure 2.2.D and Figure 2.2.E), demonstrating a 
reproducible pattern due to memory differentiation. The difference in extent of modulation is 
apparent when the PCA generated with restriction factors is overlaid on the PCA generated with 
dependency factors for peripheral blood (Figure 2.2.F) and jejunum (Figure 2.2.G). The wider 
spread of restriction factor subsets is reflective of the larger extent of expression modulation. 
  To determine if there were differences in dependency factor expression between 
peripheral blood and jejunum cells, expression in jejunum relative to peripheral blood was 
analyzed using the -ΔΔCt method, normalizing expression to the most stable endogenous 
control, POLR2A, and to the respective peripheral blood subset (Figure 2.2.C). Using a two-way 
ANOVA, the 27.5% of genes that significantly differed in their magnitude of expression between 
peripheral blood and jejunum were identified and are noted in Figure 2.2.C. Additionally, KLF2 
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was the only gene identified as exhibiting a significantly different pattern of expression among 
the memory subsets in the two tissues.  
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Figure 2.2. Expression of dependency factors generally increases in memory 
differentiation. 
Heatmap of -ΔΔCt expression values depicting memory subset expression relative to naïve for 
peripheral blood (A) and jejunum (B). Means of four animals, * = p<0.01, repeated measures 
ANOVA with Benjamini Hochberg correction. Bar graphs under each heatmap depicts mean –
ΔΔCt expression for each subset. * = p<0.05, paired T-test. Heatmap depicting expression in 
jejunum relative to peripheral blood and the most stable endogenous control, POLR2A (C). 
Unsupervised hierarchical clustering using uncentered Pearson correlation with complete linkage 
groups genes with similar expression patterns. Mean of four animals, * = p<0.05, two-way 
ANOVA testing tissue differences with Benjamini Hochberg correction. Principal component 
analysis for peripheral blood (D) and jejunum (E) based on analysis of 40 dependency factor 
genes. Overlay depicting principal component analysis of restriction and dependency factors on 
the same scale for peripheral blood (F) and jejunum (G). 
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Figure 2.2. (Continued) 
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Stimulation alters restriction factor expression 
To test if cellular activation modulated expression of restriction factors, bulk CD4+ T 
cells were isolated from the peripheral blood of four rhesus macaques and stimulated with either 
αCD3/αCD28 coupled beads or 1000 units/ml of recombinant type I human interferon-αA/D. 
CD3/CD28 activation significantly (p<0.05, t-test) modulated 36% of the genes in at least one 
time point as compared to mock stimulated cells (Figure 2.3.A). Stimulation induced both 
increases and decreases in expression of multiple restriction factors over the course of the 
experiment, showing that restriction factor expression can be dynamically modulated by 
CD3/CD28 stimulation.  This pattern of modulation of expression of restriction factors contrasts 
with that previously observed in response to PHA stimulation, which generally resulted in 
increased restriction factor expression in human CD4 T cells 320. 
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In vitro interferon stimulation increased expression of 32% of the genes compared to 
mock-stimulated cells (Figure 2.3.B). All of the restriction factors exhibiting increased 
expression have been previously found to be interferon-stimulated genes in microarray studies 
321-323. The time course exhibited a rapid modulation of responding genes as they reached peak or 
near-peak fold changes in the earliest time point post stimulation, three hours, and generally 
maintained these levels for 48 hours. Similar to memory differentiation, both TRIM5 assays were 
 
Figure 2.3. Expression of restriction factors is dynamically modulated by CD3/CD28 and 
type I interferon stimulation. 
Time course of the change in expression of selected restriction factor genes in CD4+ T cells from 
peripheral blood stimulated with antiCD3/antiCD28 beads over mock as relative to the time of 
stimulation (A). Time course of the change in expression of restriction factor genes after 
stimulation with 1000 units/ml of type I interferon, relative to the time of stimulation (B). 
Displayed here is data from the assay specific for the α isoform of TRIM5. Mean of four animals. 
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modulated in concert by interferon, indicating similar regulation of the different transcripts. 
Overall, both forms of stimulation showed that restriction factor expression can be dynamically 
modulated by external signals. However, neither form of stimulation reproduced a pattern similar 
to memory differentiation. 
 
Differences between jejunum and peripheral blood restriction factor expression 
Despite the similarities in the overall pattern of restriction factor expression between 
peripheral blood and jejunum, several differences were apparent. To determine the extent of 
variation in restriction factor expression between peripheral blood and jejunum CD4+ T cells, 
expression of restriction factors in jejunum relative to peripheral blood was analyzed using the 
ΔΔCt method 318, normalizing expression to the most stable endogenous control, B2M, and to the 
respective peripheral blood subset (Figure 2.4.A). Several genes showed more than four-fold 
greater differences: APOBEC3D in naïve, PRMT6 and TNFRSF10D in effector memory, and 
ZC3H12A in all three memory CD4+ T cell subsets. Interestingly, eight genes exhibited at least 
four-fold mean decreased expression in the CCR5+ transitional memory cells from jejunum as 
compared to the same subset of CD4+ T cells from peripheral blood. The number of restriction 
factors with decreased expression in jejunal CCR5+ transitional memory CD4+ T cells was 
much larger than the number of genes exhibiting lower expression in central memory (one) or 
effector memory (two). Using a two-way ANOVA, the genes that significantly differed in their 
magnitude of expression between peripheral blood and jejunum were identified and are noted in 
Figure 2.4.A. Additionally, genes for which the pattern of expression among the memory subsets 
differed significantly in the two tissues were identified. There were nine genes with a p-value 
less than 0.02: APOBEC3s C, D, G, and H, APOL6, CDKN1A, PARP1, SAMHD1, and TRIM5. 
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As the overall level of viral restriction mediated by these genes is likely to be cumulative, 
the overall mean expression of restriction factors from jejunum as relative to peripheral blood 
was calculated (Figure 2.4.B). This value provides a measure of the extent of overall restriction 
factor expression in each subset for which the only difference between cells was anatomic 
location. Transitional memory cells from the jejunum had a mean -ΔΔCt value of -0.819, which 
represents 0.567 fold lower expression. Using a paired T test, this decrease was statistically 
significantly different from the naïve (P=0.028) and central memory (P=0.015) subsets, though 
not for effector CD4+ T cells (P=0.115). 
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Figure 2.4. Differences in restriction factor expression in peripheral blood and jejunum 
CD4+ T cells. 
Heatmap depicting expression in jejunum relative to peripheral blood and the most stable 
endogenous control (A). Unsupervised hierarchical clustering using uncentered Pearson 
correlation with complete linkage groups genes with similar expression patterns. Mean of four 
animals, * = p<0.05, two-way ANOVA testing tissue differences with Benjamini Hochberg 
correction. Mean expression + SD (-ΔΔCt) of all restriction factors in jejunum relative to their 
respective peripheral blood subset (B). * = p< 0.05, paired T test. 
59 
 
Acute SIV infection increases expression of restriction factors in CD4+ T cells 
Given the effects of IFN stimulation and T cell activation that we observed on the 
expression of restriction factors in CD4+ T cells in vitro, we reasoned that the dynamic effects of 
acute SIV infection, which include induction of a robust type I interferon response 206,290, would 
likely have significant effects on the expression of restriction factors in vivo.  It is challenging to 
study the acute phase of immunodeficiency virus infection in humans, especially in the primary 
target tissue of the GALT. To investigate potential changes in expression of restriction factors in 
vivo during acute SIV infection, four rhesus macaques were infected intravenously with 
SIVMAC239. Ten days post-infection, animals were sacrificed and peripheral blood and jejunum 
lymphocytes were isolated. Memory CD4+ T cell subsets were sorted as before and levels of SIV 
gag RNA were quantified. In both peripheral blood and jejunum, the transitional memory 
CCR5+ CD4+ T cells were the most highly infected memory subset, as expected (Figure 2.5.A 
and 2.5.B). CD4+ T cells from jejunum in each subset were much more highly infected than 
those from peripheral blood (p=0.0058, paired T test). The reduced expression of restriction 
factors specifically in jejunum transitional memory CD4+ T cells as compared to peripheral 
blood corresponded with increased viral infection of these cells. 
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Figure 2.5. Increased SIV infection in jejunum transitional memory CD4+ T cells and acute 
infection changes in restriction factor expression. 
Gag RNA copies per cell equivalent were quantified in sorted CD4+ T cell subsets from 
peripheral blood (A) and jejunum (B). Heatmap of -ΔΔCt expression values depicting memory 
subset expression in post-infection cells relative to uninfected for peripheral blood (C) and 
jejunum (D). Means of 4 animals. * = p< 0.01, two-way ANOVA with with Benjamini Hochberg 
correction testing differences due to infection. Mean fold change of selected restriction factors 
from CD4+ T cell subsets post-infection relative to the same subset pre-infection for peripheral 
blood (E) and jejunum (F). 
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Figure 2.5. (Continued)
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Strikingly, expression of restriction factors increased in every CD4+ T cell memory 
subset from both peripheral blood (2.08 mean fold change increase) and jejunum (2.14 mean fold 
change) ten days post-infection (Figure 2.5.C and 2.5.D). On average, 43 of 46 genes increased 
expression in peripheral blood and 43 of 45 in jejunum. In particular, peripheral blood cells 
exhibited a mean increase of over 4-fold in APOBEC3H, HERC5, IFITM3A, ISG15, and MX2 
while jejunum cells increased expression of APOBEC3G, HERC5, IFITIM3A, ISG15, MX2, and 
TRIM25 more than 4-fold on average. These genes have been previously reported to be type I 
interferon-stimulated genes (ISGs) 322,323, and acute SIV infection has been well-documented to 
induce a strong type I interferon response 206. Using a two-way ANOVA with Benjamini 
Hochberg correction, approximately 2/3 of restriction factors were significantly modulated (p < 
0.01) by infection in both peripheral blood and jejunum, including the known ISGs and nearly all 
of the TRIM family members. To verify that global gene expression increase did not account for 
the restriction factor upregulation, a panel of 18 endogenous control or lineage genes such as 
CD3, CD4, CD28, etc., was confirmed to remain quite stable as compared to pre-infection (mean 
-ΔΔCt value of -0.04, or a 0.97 fold change, data not shown). The pattern of restriction factor 
upregulation was quite similar in peripheral blood compared to jejunum and naïve compared to 
memory cells despite large differences in the level of infection between the two groups, 
implicating systemic interferon or cytokine responses as drivers of upregulation. 
 
2.E. Discussion 
Here we describe precise expression measurements for 45 confirmed or putative 
restriction factors and 40 dependency factors in subsets of primary CD4+ T cells from peripheral 
blood and the jejunum, a critical site for SIV/HIV pathogenesis, under a variety of different 
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conditions. Memory differentiation induced a high dynamic range of expression of restriction 
factors. For example, we observed over 22-fold average upregulation of APOBEC family genes 
in jejunum relative to their expression in naïve CD4+ T cells. Memory differentiation increased 
dependency factor expression on average, which could contribute to the increased susceptibility 
of these cells to infection. Paired comparison of jejunum with peripheral blood CD4+ T cells 
demonstrated unappreciated differences in restriction factor expression that could underlie 
differences in their susceptibility to SIV infection. Specifically, CCR5+ CD4+ T cells from 
jejunum showed reduced expression of restriction factors relative to the CCR5+ CD4+ T cells 
from peripheral blood.  
In general, memory differentiation had similar effects on expression of restriction factors 
in both tissue compartments, increasing average restriction factor expression. Activation of bulk 
populations of CD4+ T cells has been shown to increase restriction factor expression 320, and 
both CD3/CD28 and interferon stimulation dynamically modulated expression of restriction 
factors. However, despite the overall increased expression of restriction factors in memory CD4+ 
T cells, they are well documented to be more susceptible to SIV and HIV infection 283,284.  This 
increased susceptibility is likely to reflect factors other than restriction factors that modulate 
infection, such as T cell activation as well as the ability of SIV to counteract the effects of 
restriction factors by various mechanisms, including the effect of Vif on APOBEC3G, Nef on 
Tetherin, and Vpx on SAMHD1 92,324.  
The Fluidigm Biomark qRT-PCR system used in this study allows for high-throughput, 
highly quantitative, and precise gene expression measurements with a wide dynamic range of 6-8 
orders of magnitude, significantly wider than microarray based systems 325. In addition, the 
specificity of the primer/probe real-time PCR assays permitted discrimination of specific 
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transcript isoforms. TRIM5 is known to be expressed as multiple isoforms in humans. Only the 
TRIM5α isoform containing the C-terminal SPRY domain is capable of restricting HIV/SIV 
while other isoforms can act in a dominant negative fashion to inactivate the α isoform 317. Here 
we found that the α isoform is present at about 50% of the abundance of total TRIM5 in primary 
CD4+ T cells from both jejunum and peripheral blood. However, various forms of stimulation 
including memory differentiation, CD3/CD28, interferon, and SIV infection did not appreciably 
alter the relative abundance of the α isoform to that of total TRIM5 despite altering the total level 
of expression. 
This study utilized the advantages of the rhesus macaque/SIV model to understand the 
expression changes of restriction factors in primary cells and cells from tissues that are difficult 
to study in humans, especially during acute infection. In particular, mucosal tissues are the 
primary site of transmission and the major site for replication and CD4+ T cell depletion in 
HIV/SIV infection 163,165,180,289. Infection of CD4+ T cells in peripheral blood is relatively 
infrequent, 0.1 to 1%, while up to 60% of mucosal CD4+ T cells can be infected during acute 
infection 165,283. Here we observed increased levels of infection in each CD4+ T cell subset in 
jejunum as compared to peripheral blood, verifying mucosal CD4+ T cells as particularly 
susceptible targets. Though precise mechanisms remain unclear, multiple hypotheses have been 
proposed to explain this increased susceptibility to SIV/HIV infection, including a greater 
proportion of CCR5-expressing cells, fewer naïve cells, more activated cells with higher levels 
of transcription, the closer proximity of target cells facilitating cell-cell spread, and additional 
factors such as increased α4β7 expression facilitating the binding of virions 13. Here we show 
that in the CCR5-expressing transitional memory subset with the same phenotype from 
peripheral blood and jejunum, cells from jejunum expressed relatively lower levels of restriction 
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factor genes and that memory cells expressed higher levels of dependency factor genes, both 
potentially contributing to their increased levels of infection. 
Previous studies have measured the expression of a subset of the restriction factors 
included in this study under certain conditions. For example, PBMCs from HIV-naïve subjects 
stimulated with PHA induced upregulation of genes such as ISG15, APOBEC3G, and TRIM5 320. 
Interferon-α treatment of HIV/HCV co-infected patients resulted in the upregulation of a subset 
of restriction factor genes like ISG15 and TRIM19 (PML) in agreement with our results 203,326. 
However, these studies measured restriction factor expression in either total PBMCs or total 
CD4+ T cells. As shown in this study, restriction factor expression can vary significantly among 
different memory subsets. Therefore, analysis of expression of specific restriction factors in 
specific populations of target cells may be more informative than analysis in bulk populations of 
CD4+ T cells. 
We demonstrated dynamic modulation of restriction factor expression in CD4+ T cells 
due to differentiation, activation, interferon stimulation, and SIV infection. All forms of 
stimulation induced different patterns of expression of restriction factors. For example, memory 
differentiation increased expression of all APOBEC family members, while anti-CD3/CD28, 
interferon, and SIV infection increased expression of only selected APOBEC genes. Differential 
effects of stimulation suggest different mechanisms of regulation. Acute SIV infection is known 
to induce robust upregulation of interferon expression 206,290. Acute SIV infection increased 
expression of nearly every gene while in vitro interferon stimulation induced expression of only 
32% of the measured restriction factors, suggesting type I interferon alone is insufficient to 
account for the full range of expression modulation during infection. Previous studies have found 
a wide range of cytokine/chemokine production during acute SIV/HIV infection 199,327, and 
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future studies will be required to determine the specific contributions of these signals to 
restriction factor regulation.  
Recent research shows that innate immune responses may be suppressed in the first days 
post-infection thus allowing viral replication to progress 328. In this study, nearly all of the 
restriction factors increased in expression in both peripheral blood and jejunum CD4+ T cells at 
10 days post-infection, with interferon-stimulated genes exhibiting the greatest extent of 
upregulation. While these restriction factors may play a role in inhibiting SIV replication, this 
dramatic upregulation does not occur until after systemic infection has been established. The 
kinetics of restriction factor expression changes during the earliest phases of acute pathogenic 
infection are still unknown, including if cells at the earliest sites of viral replication display gene 
expression changes before peripheral cells. Additionally, it is still unknown if differences in 
restriction factor expression may underlie differences in susceptibility to infection at the 
organismal level. 
Taken together, these data highlight the dynamic regulation of expression of restriction 
and dependency factors, which can be modulated by multiple factors including cell 
differentiation, anatomic compartment, T cell activation, and acute SIV infection.  Although 
other factors are clearly relevant, modulation of expression of restriction and dependency factors 
is likely to play a significant role in the wide range of differential susceptibility of distinct CD4+ 
T cell subsets to SIV infection.  Future studies will be necessary to better to define the roles of 
individual restriction or dependency factors to the susceptibility of primary CD4+ T cells to SIV 
infection.   
  
  
Chapter 3: Identification and characterization of a highly SIV-susceptible population of 
Tfh-like cells in rhesus macaque jejunum by single cell gene expression analysis 
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3.A. Abstract 
 Despite extensive study, our understanding of the molecular events that determine the 
susceptibility of CD4+ T cells to SIV and HIV infection and the cellular events that follow 
lentiviral infection have been limited by our ability to track events that occur in single cells and 
analyze gene expression, including viral gene expression, on a single cell basis. New techniques 
that permit high-throughput analysis of gene expression in single cells can be used to 
deconvolute cell types in apparently homogenous populations of bulk cells and offer the 
potential to provide new insights into AIDS pathogenesis. Here we utilized acutely simian 
immunodeficiency virus (SIV)-infected rhesus macaques to isolate individual infected and 
uninfected CD4+ T cells from the intestinal mucosa, the primary site of viral replication in acute 
infection. Using high-throughput microfluidic quantitative real-time PCR of single cells, we 
measured expression of five viral transcripts used to define SIV-infected cells along with 91 
cellular genes chosen for potential relevance in the viral replication cycle.  
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 Single cell analysis of over 300 single jejunal CD4+ T cells obtained 10 days after 
intravenous SIV infection revealed that approximately 20% of these cells were SIV-infected. 
Comparison of gene expression profiles using multiple statistical methods identified PD-1 and 
CXCR5 as being the most significantly differentially expressed genes between infected and 
uninfected cells, and the coexpression of both genes was observed more frequently in infected 
cells.  
The coexpression of PD-1 and CXCR5 on CD4+ T cells defines T follicular helper (Tfh) 
cells. However, the existence of a Tfh population in the jejunum has not previously been 
described. Using flow cytometry, we found a discreet population of PD-1+ CXCR5+ memory 
CD4+ T cells in the jejunum of uninfected animals with a frequency intermediate to that found in 
peripheral blood and lymph nodes. This jejunal PD-1+ CXCR5+ cell population expressed 
surface markers ICOS, CD69, CTLA4, CCR5, CD200, and the canonical Tfh transcription factor 
BCL6 protein at similar levels to classical Tfh populations from lymph node or spleen. 
Additionally, the expression profile of over 70 Tfh-associated genes in the PD-1+ CXCR5+ cells 
from jejunum was remarkably similar to classical Tfh cells, including the canonical Tfh cytokine 
IL-21. This novel population exhibits many phenotypic and transcriptional characteristics of Tfh 
cells, yet is found in a location that has not been generally considered to be an inductive site. 
While circulating Tfh cells have been described in peripheral blood, the jejunal population 
described in this study was found at a much higher proportion of memory CD4+ T cells and 
expressed BCL6 protein as well as the activation markers CD69 and ICOS, differentiating it 
from circulating Tfh cells.  
PD-1+ CXCR5+ cells from jejunum were found to be highly SIV-infected, with an 
average of over three SIV DNA copies/cell at the peak of acute infection. This level of infection 
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higher than that of bulk memory CD4+ T cells was observed despite low levels of cell surface 
expression of the SIV coreceptor CCR5. This study is the first single cell gene expression 
analysis of primate lentivirus-infected cells, and it identified a novel and highly susceptible target 
cell population in vivo during acute infection. 
 
3.B. Introduction 
Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infect 
CD4+ cells through their use of CD4 as a primary receptor and a chemokine receptor (the two 
most common are CCR5 and CXCR4) as a coreceptor for entry into cells 29,30. Cells that express 
these receptors and are therefore potentially susceptible to infection include CD4+ T cells, CD4+ 
monocytes 329,330, macrophages 331, thymocytes 332, some subsets of dendritic cells 333, some 
subsets of hematopoietic progenitor cells 334,335, and CNS macrophages including microglial cells 
336,337 . However, expression of the proper receptors alone is not sufficient to explain a cell’s 
susceptibility to infection by immunodeficiency viruses. Many additional parameters have been 
suggested to influence susceptibility, though the relative contributions of these factors remain 
undefined. The level of cell surface receptor or coreceptor 338 and the level of autocrine CCR5-
binding chemokine production that influences receptor availability 93 can impact susceptibility, 
as can the presence of α4β7 on the cell surface, which HIV and SIV are capable of binding 339,340. 
Cell activation, although not well-defined molecularly, also influences whether a cell can be 
infected, potentially through multiple mechanisms. For example, to achieve efficient infection in 
vitro T cell-activating agents like ConA are generally used. Additionally, spinoculation, thought 
to work by physically concentrating virus, has recently been reported to function by increasing 
cell activation by actin- and cofilin-mediated responses to centrifugal stress 341. Similarly, the 
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memory status of a cell (if a cell is antigen-experienced) influences its susceptibility 283,284. The 
expression of restriction factors can influence susceptibility, for example the expression of 
SAMHD1 in non-cycling cells renders them resistant to HIV infection by depleting nucleotide 
pools necessary for reverse transcription 104. Finally, other markers for susceptibility without a 
known mechanistic link to viral infection such as CCR6 expression (a marker for TH17 cells) 
have been described 342. In total, although many single parameters contributing to HIV and SIV 
infection have been identified, often using in vitro studies, a complete molecular description of 
the characteristics of the subsets of CD4+ T cells that are susceptible to HIV/SIV infection in 
vivo is still lacking. To that end, this study focused on primary cells and simultaneously analyzed 
multiple factors in individual cells. 
Accumulating evidence emphasizes that the mucosal immune system, and specifically the 
intestinal immune system, is central to the HIV/SIV infection course. The majority of natural 
transmissions of HIV are across a mucosal barrier and the virus primarily replicates in and 
depletes gut CD4+ T cells 163,165,166,180. Despite the clear importance of mucosal immune tissue in 
the initiation and progression of infection, cells from mucosal tissues are relatively understudied 
as compared to cells from peripheral blood due to the difficulty in obtaining tissue samples 289. 
This emphasizes the utility of non-human primates in studying immunodeficiency virus 
infections since the time of infection is precisely known and sufficient tissue samples can be 
obtained. Additionally, there are many similarities in the viruses, hosts, and disease pathogenesis 
between HIV in infection in humans and SIV in rhesus macaques 164. 
Widely used methods to measure gene expression such as microarrays and quantitative 
real-time PCR (qRT-PCR) generally analyze relatively large numbers of cells (106 or more). As 
a result, analysis of gene expression in these studies reflects an average of all the cells in the 
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sampled population. Gene expression on a single cell level is variable such that even 
housekeeping genes in genetically identical cells have a broad range of gene expression values 
278. This variability can be due to the intrinsic stochastic nature of biochemical processes 
regulated by a small number of molecules and extrinsic sources such as the cell cycle and the 
unique signals from the local microenvironment 277,279. Therefore, measurements that average 
expression over multiple cells can obscure differences among subpopulations. Single cell 
measurements can deconvolute cell types in putatively homogenous populations to discover the 
identity and gene expression profiles of subpopulations, even if they are rare 278. 
Multiple studies have attempted to characterize differences in gene expression between 
HIV-infected cells and uninfected cells 343-347. Potential confounding factors in vitro include use 
of cell lines; infection with super-physiological levels of virus resulting in infection of cells that 
may not be infected in vivo; cell stimulation to increase infection rates which alters gene 
expression; and using mock-infected cells rather than cells that do not become infected as a 
comparison to virus-exposed cells. In in vivo studies, gene expression measurements are 
averages of many cells. As even during the peak of infection in highly susceptible mucosal tissue 
only about 50% of memory CD4+ T cells are infected 165, bulk gene expression measurements 
are averages of both infected and uninfected cells. No study to date has measured gene 
expression on a single cell basis in HIV- or SIV-infected CD4+ T cells as compared to individual 
uninfected cells. 
T follicular helper cells (Tfh) are a subset of CD4+ helper T cells specialized for 
providing help for B cells 152. They are essential for germinal center formation, affinity 
maturation, class-switch recombination, and allow the formation of plasma cells and long-lived 
memory B cells. A number of recent publications have resulted in a rapid expansion of our 
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understanding of the importance of Tfh cells in HIV/SIV infection. In chronic untreated HIV-
infected patients Tfh cells were found to be the major T cell compartment for HIV infection, 
replication, and production 269, and an important site of viral persistence in chronic infection 271. 
Tfh cells are generally located in germinal centers in secondary lymphoid tissues and can be 
found in low frequency in the periphery, though these cells express lower levels of CXCR5, 
BCL-6, ICOS, and PD-1 348,349. There is only limited evidence for Tfh cells in non-lymphoid 
mucosal tissue. One of the only studies looking for PD-1high cells in jejunum failed to find any 
during chronic SIV infection, suggesting that either they are depleted or that they are not present 
due to limited GALT structures in jejunum 350. Limited recent evidence suggests Tfh or Tfh-like 
cells can exist in mucosa sites. Mycobacterium tuberculosis-specific PD-1high cells residing in the 
lung parenchyma required intrinsic Bcl6 and ICOS expression for their generation, and a fraction 
of these cells co-expressed CXCR5 351. Additionally, in a humanized-DRAG mouse model 
human Tfh cells were found in gut lamina propria at about 1/3 the frequency of that in Peyer’s 
patches or mesenteric lymph nodes 352. 
In this study, we utilized high-throughput single cell RT-PCR to analyze gene expression 
from single jejunum CD4+ T cells from acutely SIV-infected rhesus macaques. Comparison of 
gene expression between SIV-infected and uninfected T cells revealed PD-1 and CXCR5 as the 
most significantly differentially expressed genes, and both genes were enriched in SIV-infected 
cells. Together PD-1 and CXCR5 can define Tfh cells; however, Tfh cells have not been 
described in jejunum tissue lacking organized secondary lymphoid tissue. A PD-1+ CXCR5+ 
population of memory CD4+ T cells was identified by flow cytometry in the jejunum of 
uninfected animals, and these cells were found to express many phenotypic markers associated 
with Tfh cells at similar levels to Tfh cells isolated from spleen or lymph node. Additionally, 
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they expressed the canonical Tfh transcription factor BCL6 protein and IL-21 mRNA. To 
rigorously compare the gene expression profile of this novel population to classical Tfh cells 
from secondary lymphoid tissues, we examined the expression of 77 Tfh-associated genes in PD-
1+ CXCR5+ cells from jejunum and lymph nodes.  PD-1+ CXCR5+ cells from jejunum exhibits 
a characteristic Tfh signature of gene expression, clustering with Tfh cells from lymph nodes by 
hierarchical clustering and principal component analysis. The PD-1+ CXCR5+ cells from 
jejunum were found to contain high levels of SIV DNA and RNA during acute infection, 
showing these cells are particularly susceptible to infection and suggesting that they are depleted 
rapidly. 
 
3.C. Materials and Methods 
Animals 
The eight Indian-origin rhesus macaque monkeys (Macaca mulatta) described in this 
study were housed at the New England Primate Research Center (NEPRC) in accordance with 
the regulations of the American Association of Accreditation of Laboratory Animal Care and the 
standards of the Association for Assessment and Accreditation of Laboratory Animal Care 
International.  All protocols and procedures were approved by the relevant Institutional Animal 
Care and Use Committee. Care met the guidance of the Animal Welfare Regulations, OLAW 
reporting, and the standards set forth in The Guide for the Care and Use of Laboratory Animals 
291. Euthanasia took place at seven or ten days post-infection using protocols consistent with the 
American Veterinary Medical Association (AVMA) guidelines. 
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Lymphocyte isolation 
Jejunum tissue was isolated at time of euthanasia, washed with PBS, separated into small 
pieces with a scalpel, incubated with 5 mM EDTA for 30 min, washed and incubated with 15 
U/ml type II collagenase (Sigma-Aldrich) followed by mechanical disruption with an 18 gauge-
feeding needle and filtration through 70 μm cell strainers (BD Biosciences). Lymphocytes were 
then enriched by bilayer (35%/60%) isotonic Percoll density gradient centrifugation (1000 × g, 
20 min), and the interface containing the lymphocytes was collected 292.  
Spleen lymphocytes were isolated by briefly disrupting the tissue with a scalpel, filtering 
through a 70 um cell strainer, lysing red blood cells with ACK buffer, and washing. 
Lymph node cells were isolated by disrupting the capsule, filtering through a 70 μm cell 
strainer, and washing. 
Peripheral blood mononuclear cells (PBMC) were separated by density gradient 
centrifugation (Lymphocyte Separation Medium; MP Biomedicals Inc., Solon, OH) and red 
blood cell lysis with ACK buffer. Cells were cryopreserved in FBS media containing 10% 
DMSO. 
 
Antibodies and cell sorting 
To sort memory CD4+ T cells for single cell gene expression analysis, PBMC were 
stained with CD3 (SP34)-Pacific Blue, CD4 (L200)-FITC, CD8 (RPA-T8)-Alexa 700, CD28 
(28.2)-ECD (Beckman Coulter), CD95 (DX2)-APC, CCR5 (3A9)-PE, and CCR7 (2D12)-PE-
Cy7. Antibodies were obtained from BD Pharmingen unless otherwise specified. PBMCs were 
initially labeled with LIVE/DEAD viability stain (Life Technologies) and washed; incubated 
with the CCR7 antibody for 15 min at 37°C, and then incubated with all other antibodies for 20 
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min at room temperature and washed prior to sorting. Cell sorting was performed using a FACS 
Aria II cell sorter (BD Biosciences). Sorted cell populations were > 99% pure. 
A phenotyping panel for Tfh-like cells included Live/Dead stain, CD3(SP34.2)-BV650, 
CD4(L200)-APC-Cy7, CD8(RPA-T8)-Alexa 700, CD28(CD28.2)-FITC, CCR5(3A9)-APC, 
CCR7(150503)-BV711, CD200(MRCOX104)-PerCP-Cy5.5, CTLA4(BN13)-PE-Cy5, 
CD95(DX2)-PE-Cy7 (eBiosciences), CXCR5(MU5UBEE)-PE (eBiosciences),  
PD-1(EH12.2H7)-BV421 (BioLegend), CD278/ICOS(398.4A)-PerCP-Cy5.5 (BioLegend), and 
CD69(TP.55.3)-ECD (Beckman Coulter). Additional antibodies used included BCL6(K112-91)-
Alx-647, CD200(MRCOX104)-PerCP, and CCR7(150503)-ECD. 
Intracellular BCL6 was performed by washing cells with PBS and staining with 
Live/Dead dye. After cell surface staining, cells were treated with 1mL Transcription Factor 
Fix/Perm(1X) solution (Tonbo Bioscience) for 30 min at 4°C and then washed 2 times with Flow 
Cytometry Perm Wash buffer (1X) (Tonbo). Cells were incubated with 5uL antibody 
recognizing nuclear antigen BCL6(K112-91)-Alx-647 at 40°C for 30 mins. 
Flow cytometry was performed on a LSRII cytometer (Becton Dickinson) and analyzed 
with FlowJo V10 software. 
 
Gene expression analysis 
Real-time PCR assays specific for the indicated rhesus macaque genes were purchased 
from Applied Biosystems (ABI) (Table 3.1). When not commercially available, macaque-
specific custom assays with FAM-MGB probes were designed using Primer Express 3.0 (ABI). 
Sequences for custom assays were: APOL6 F-AGGCAGAGGAAGAAAGTGAAGCT,  
R-TCGTCTTCACACAGAGGAACATCT, P-TTGGTTTGGAAAGGGATGAG; CXCR4  
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F- ACCGCGTCTGGAGAACGA, R- TCCCCTGAGCCCATTTCC, P- 
ATGGAGGGGATCAGTATATA; CXCR5 F- CCGCTAATGCTGGAAATGGA,  
R- TGTCGTTATAGTTGTCGAATTTGTCA, P- TGGAGGACCTGTTCTT; IFITM3A  
F-GGCCAGCCTCCCAACTATG, R-GGGCGCCCCCATCAT, P-AAGAGCACGATGTGGC; 
IFITM3B F-AAACCGTCTTCCCTCCTGTCA, R-GCTACCTCATGCTCTTCCTTGAG,  
P-CCCCCCAGCTATGAG; PIP5K1C F- TGCACATTGGCATCATTGATATC,  
R- CCAGGTGTGCTCCAGCTTCT, P- CAATCCTACAGGTTCATC; RORC  
F- TGAGAAGGACAGGGAGCCAA, R- CCACAGATTTTGCAAGGGATCA,  
P- TCATGAGAACACAAATTGA; RGS1 F- CAGATGCTGCTAAACAAATCAATATTG,  
R- AGGGTTGGTGCTTTAATCTTCTTG, P- TTCCGCACTCGAGAAT; TRIM14  
F-CAGCCAGGAGCCTGATCCT, R-CCGCTGCATCTCCTGCTT,  
P-AGAGGCTTCAGGCATACA; SPG7 F- AGAAGAATAAGGAGAAGGATAAGTCGAA; 
TRIM32 F-GGCCTCAATCTGGAGAATCG, R-AACCAATGGAAAAGCCACCTT,  
P-CAGAATGAGCACCACCTG; UBASH3A F- GAAGCCAGCAGCAGATGCA,  
R- CCACCAGCACGCTCTTCCT, P- CCTTGCAGGCCACCG. 
All assays were confirmed to exhibit linear amplification in an eight point, three-fold 
dilution series of rhesus PBMC cDNA. 
 
SIV assay design and optimization 
 In order to distinguish infected from uninfected cells, real-time PCR assays were 
designed specific for SIVmac239 sequences. Two classes of assay were used: one that detects 
sequences present in the viral genome, including Gag, LTR, and R region sequences, and one 
that spans splice junctions such that the recognition sequence is present only in spliced products 
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of viral transcription. These included a singly spliced Env transcript and the multiply spliced Tat-
Rev transcript. As there are significantly more viral particles that do not successfully complete a 
replication cycle than those that do 353, detecting spliced transcripts in a cell identifies a cell that 
has been productively infected. Three of the SIV assays were generously provided by Jeff Lifson 
(NCI Frederick): Gag, LTR, and Tat-Rev.  
Primer sequences for the SIV assays were: SIV gag  
F-GUCUGCGUCAUCUGGUGCAUUC, R-CAAAACAGAUAGUGCAGAGACACCUAGUG, 
P- CGCAGAAGAGAAAGUGAAACACACUGAGGAAG; SIV LTR  
F- CTAACCGCAAGAGGCCTTCTT, R- TTGTGGAAAGTCCCTGCTGTT,  
P- ACATGGCTGACAAGAAGGAAACTCGCTG; SIV R Region  
F- GGAGAGGCTGGCAGATTGAG, R- ACCCAGGCTCTACCTGCTAGTG,  
P- CCTGGGAGGTTCTC; SIV major splice F- TTGCAGAGGCGGATGCAT,  
R- GCGGTATAGCTGAGAGAGGATTTC, P- CACTCCAGAATCGGCCA; SIV Tat-Rev  
F- GCTAAGGCTAATACATCTTCTGCATC, R- CCGTCTCTTTCTTTGCCTTCTC,  
P- AACAGGACCCGGCACTGCCAAC. 
All SIV-specific assays were tested for sensitivity and specificity in bulk in vitro infected 
CD4+ T cells using the same RNA extraction, cDNA conversion, and qRT-PCR protocols to 
ensure compatibility with cellular gene qRT-PCR assays measured using the Fluidigm Biomark 
system. 
 
Acute SIV infection 
Eight Indian-origin rhesus macaques were infected intravenously with a 500 50% tissue 
culture infective dose (TCID50) of SIVmac239 (generously provided by Francois Villinger 
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(Emory University)). Four animals were sacrificed at day seven post infection and four animals 
were sacrificed at day 10 post infection. PBMCs were isolated pre-inoculation and a CD4 
phenotyping flow panel was used to analyze CD4 subset frequencies. Cells and tissue were saved 
from blood, spleen, axillary LN, mesenteric LN, genital LN, bone marrow, and jejunum at the 
time of sacrifice. The phenotyping flow panel was run on fresh PBMC, spleen, axillary LN, 
mesenteric LN, and jejunum cells from the day seven and 10 animals. 
 
Single Cell qRT-PCR 
To obtain a pure population of CD95+ memory CD4+ T cells from jejunum, cells were 
sorted in a FACS Aria II cell sorter (BD Biosciences) into cold media. Sorted cell populations 
were > 99% pure. Cells were pelleted, resuspended at 1000 cells/μl, and final concentration of 
60% cell suspension reagent was added. Approximately 5 μl (2000 cells) were loaded into a 
primed 5-10 μm capture site size integrated fluidic circuit (IFC) for the C1 Single Cell Autoprep 
System (Fluidigm), and stained with calcein AM live/EtBr dead dye using the cell stain script. 
Each capture site was visualized and the number of cells captured and their viability status 
recorded. The system performed lysis, reverse transcription, and specific target pre-amplification 
for 18 cycles with 0.2x concentration primer mix. The resulting cDNA was harvested, diluted 1:3 
with DNA dilution reagent, and prepared for qRT-PCR. Output was analyzed on a Fluidigm 
BioMark microfluidic real-time PCR system using 96.96 dynamic arrays. 4.5 μl of diluted cDNA 
was mixed with TaqMan Universal Master Mix II with UNG (ABI) and a 1x final concentration 
of 20 GE loading buffer. 7 μl of each cDNA sample was loaded into sample wells of the 96.96 
dynamic array while 20x concentration RT-PCR assays with loading reagent were added to the 
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assay wells. Initial calculations of cycle thresholds (Ct) were performed using the Fluidigm 
BioMark software version 4.1.3. 
 
Plasma viral loads 
Plasma viral RNA levels were quantitated using real-time PCR, and SIV RNA copy 
number was determined by comparison to an external standard curve 354,355. 
 
Cell-associated SIV DNA and RNA 
 DNA and RNA were extracted from sorted cell populations using an AllPrep DNA/RNA 
Micro Kit (Qiagen). A DNA standard with a known copy number was used to quantify Gag 
DNA copies, and a genomic CCR5 standard was used to quantify the copies of CCR5 in the 
sample. This verified the cell numbers in each sample and allowed for calculations of SIV Gag 
DNA copies per cell. Samples were tested on an ABI 7900 quantitative real-time PCR 
instrument and analyzed with ABI SDS 2.4 software. 
 RNA was quantified in reference to a SIV Gag standard curve of known copy number 
composed of in vitro transcribed RNA converted to cDNA. Both the standard curve and the 
cellular sample cDNAs were tested with a SIV Gag qRT-PCR assay and measured using the 
Fluidigm Biomark system. 
 
Statistical analysis 
Statistics and graphing were performed using GraphPad Prism version 6.05 for Windows 
(GraphPad Software, La Jolla California) or R 293. Heatmaps were generated using GENE-E 
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(http://www.broadinstitute.org/cancer/software/GENE-E/index.html) and principal component 
analysis coordinates were obtained using MEV version 4.9 356 and visualized in Prism. 
 When comparing gene expression at the single cell level, normal statistical distributional 
assumptions are violated, and regular Poisson or negative binomial regression models cannot fit 
the data effectively. We implemented a zero-inflated Poisson (ZIP) regression approach under 
the guidance of Wenjun Li, a biostatistician at the University of Massachusetts Medical School. 
This provides three p-values, one for the odds ratio of discrete expression, one for the rate ratio 
of continuous expression, and a joint test. 
 
3.D. Results 
Cellular gene assay selection 
As qRT-PCR requires selection of target genes, a panel of about 90 rhesus genes was 
chosen on the basis of likely involvement in the SIV lifecycle, differential expression, and 
detectable expression in primary rhesus CD4+ T cells. Categories of genes selected for analysis 
included: genes that could define cell lineages such as CD3, CCR7, and CCR6; viral entry genes 
such as CD4 and CCR5; lymphocyte activation associated genes such as NFKB1; restriction 
factor genes such as TRIM5 and APOBEC3G; dependency factor genes such as nucleoporin and 
mediator complex genes; and genes whose expression changed upon HIV infection 346.  
Many restriction factors - genes that serve as an intrinsic host defense against virus 
infection - have well-described activity against primate lentiviruses, including the APOBEC3 
DNA deaminase family, the TRIM family, BST-2/Tetherin, and SAMHD1 92. Screens have also 
been performed to identify other restriction factors. A whole genome siRNA screen identified 
putative restriction factors such as the PAF1 complex and exosome components 119. A screen for 
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genes sharing genomic characteristics of known restriction factors identified APOL and TNFRSF 
family members 287. 
Host dependency factors are genes that the virus uses to complete its replication cycle. A 
number of these are well-described, such as receptors for entry, proteins involved in nuclear 
import (nucleoporin genes) 55, or proteins involved in integration such as LEDGF 357. Genes that 
have been shown to be involved in the HIV or SIV lifecycle were prioritized for inclusion in our 
panel. Dependency factors have been identified in multiple genome-wide siRNA screens that 
resulted in thousands of total hits 15-18. Since it is not practical to analyze expression of thousands 
of genes using high-throughput single cell RT-PCR, it was necessary to identify a subset of these 
putative dependency factors for analysis. Since the screens used different target cells, viruses, 
and siRNA libraries, genes that were identified on two or more screens are less likely to 
represent off target results, Many of these genes have been included in the list. Additionally, a 
follow-up study to one of the RNAi screens 17 has verified a set of 108 genes that have been 
scored as hits using multiple siRNA libraries in which the genes scored positive using at least 
two independent libraries 21.  
To rationally pick the most differentially expressed genes from the dependency factors 
and other gene sets, we used Gene Set Enrichment Analysis (GSEA). GSEA is a computational 
method used to determine if a set of genes is statistically significantly enriched in a given ranked 
list 358. There are two necessary components: a large list of genes ranked by some biological 
criteria (such as high to low expression) and a probe set of genes. To generate the ranked list, 
gene expression in human naïve, central memory, and effector memory CD4+ T cells from a 
genome-wide microarray gene expression study 359 was used and ranked by an F-test. The F-test 
is an ANOVA statistic to compare the means of multiple groups at the same time. Ranking all 
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22,944 probes in this data set by F-test result generated a list of the genes from the most 
differentially expressed to the least differentially expressed in these cell types. To probe the 
ranked list using GSEA, the dataset of 108 genes identified as putative host dependency factors 
was used. The GSEA algorithm walks down the ranked list and increases a weighted running 
statistic (the enrichment score or ES) when a gene on the ranked list is found in the probe set and 
decreases the ES when the ranked list gene is not on the probe set. The algorithm generates two 
results. First, it determines whether the probe set as a whole is statistically significantly enriched 
on the ranked list, and second, the algorithm reports the point at which the Enrichment Score 
reached its peak and started declining. The genes in the probe set that contributed to the rising 
peak of the ES are called the leading edge. These leading edge genes represent the most 
differentially expressed genes in the probe set; for a set of 108 dependency factors, this leading 
edge was 22 genes. 
Using the same F-test ranked list of gene expression in CD4+ T cell subsets, the ranked 
list was probed with a list of 118 putative HIV restriction factors 119 generating a leading edge of 
37 genes. Additionally, GSEA was used to narrow down a list of NF-kB responsive genes 
generating a leading edge of 63 genes, and a list of 498 genes that were differentially expressed 
in HIV infected versus uninfected CD4+ T cells 346 generating a leading edge of 92 genes. Genes 
from each category were selected, assays chosen, and gene expression measured in bulk CD4+ T 
cell memory subsets with or without stimulation. Genes with differential expression between 
conditions and detectable expression in 200 cell equivalents were prioritized for inclusion in the 
final panel (Table 3.1). 
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Table 3.1. List of genes selected for single cell expression analysis.   
Assay ID numbers are provided for the ABI TaqMan assays; sequences for the custom assays are 
provided in the text. DEG = Differentially Expressed Gene. 
Gene Name Category ENTREZ ID Mm 
ENTREZ 
ID human HGNC Full Name Assay ID Ref 
BCL6 Lineage 708736 604 B-cell CLL/lymphoma 6 Rh02839507_m1  
CCR6 Lineage 574335 1235 C-C motif chemokine receptor 6 Rh02788181_s1  
CCR7 Lineage 574231 1236 C-C motif chemokine receptor 7 Rh03985963_s1  
CD28 Lineage 705313 940 CD28 molecule Rh02621766_m1  
CD3e Lineage 699467 916 CD3e molecule Rh01062242_m1  
CXCR5 Lineage 701792 643 C-X-C motif chemokine receptor 5 Custom  
GATA3 Lineage 713840 2625 GATA binding protein 3 Rh02830714_m1  
IL17A Lineage 708123 3605 interleukin 17A Rh02621750_m1  
PDCD1 / PD-1 Lineage 100135775 5133 programmed cell death 1 Rh03418231_m1  
RGS1 Lineage 712754 5996 regulator of G-protein signaling 1 Custom  
RORC Lineage 717052 6097 RAR related orphan receptor C Custom  
TBX21 / T-bet Lineage 694044 30009 T-box 21 Rh02621772_m1  
CCR5 Lineage / Entry 735311 1234 C-C motif chemokine receptor 5 Rh03043152_s1  
CD4 Lineage / Entry 713807 920 CD4 molecule Rh02621720_m1  
CXCR4 Lineage / Entry 707329 7852 C-X-C motif chemokine receptor 4 Custom  
GPR15 Lineage / Entry 698718 2838 G protein-coupled receptor 15; BOB Rh02786977_s1 31 
Fos Activation 702077 2353 Fos proto-oncogene, AP-1 transcription factor subunit Rh01119267_m1  
LGALS3 Activation 697290 3958 lectin, galactoside binding soluble 3 Rh02841801_m1  
NFKB1 Activation 710324 4790 nuclear factor kappa B subunit 1 Rh00765726_m1  
S100A4 Activation 715115 6275 S100 calcium binding protein A4 Rh02818677_m1  
TNFRSF1B Activation 715454 7133 TNF receptor superfamily member 1B Rh02837327_m1  
VIM Activation 705289 7431 vimentin Rh00958113_m1  
APOBEC3G Restriction 574398 60489 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G Rh02788475_m1 
115,11
6,299 
APOL6 Restriction 693593 80830 apolipoprotein L, 6 Custom 
95,287
,360 
CDKN1A Restriction 719199 1026 cyclin-dependent kinase inhibitor 1A (p21, Cip1) Hs00355782_m1 
302,30
3 
EXOSC3 Restriction 716347 51010 exosome component 3 Rh02830694_m1 119 
GSN Restriction 699705 2934 gelsolin (amyloidosis, Finnish type) Rh02794823_m1 304 
IFITM1 Restriction 697687 8519 interferon induced transmembrane protein 1 (9-27) Rh02809735_gH 
94 
IFITM3A Restriction 697829 10410 [predicted] interferon induced transmembrane protein 3-like Custom 
94 
IFITM3B Restriction 697564 10410 [predicted] interferon induced transmembrane protein 3-like Custom 
94 
ISG15 Restriction 700141 9636 ISG15 ubiquitin-like modifier Rh02915441_g1 305 
MX2 Restriction 780935 4600 myxovirus (influenza virus) resistance 2 (mouse) Rh02801425_m1 
131,13
3 
PAF1 Restriction 697786 54623 Paf1, RNA polymerase II associated factor, homolog (S. cerevisiae) Rh02876261_m1 
119 
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Table 3.1. (Continued) 
Gene Name Category 
ENTREZ 
ID Mm 
ENTREZ 
ID human HGNC Full Name Assay ID Ref 
PRMT6 Restriction 694284 55170 protein arginine methyltransferase 6 Rh02817860_s1 
310,31
1 
RPRD2 - REAF Restriction 715526 23248 regulation of nuclear pre-mRNA domain containing 2; REAF Rh02868968_m1 
119,12
0 
SAMHD1 Restriction 709060 25939 SAM domain and HD domain 1 Rh02869977_m1 
104,10
7 
TNFRSF10A Restriction 716826 8797 tumor necrosis factor receptor superfamily, member 10a Rh02846752_m1 
287 
TRIM14 Restriction 715418 9830 tripartite motif-containing 14 Custom 95 
TRIM19 – PML Restriction 700379 5371 promyelocytic leukemia Rh03043124_m1 312 
TRIM22 Restriction 713814 10346 tripartite motif-containing 22 Rh02801450_m1 
129,31
3,314 
TRIM32 Restriction 702595 22954 tripartite motif-containing 32 Custom 315 
TRIM34 Restriction 100568287 53840 
TRIM6-TRIM34 readthrough transcript; 
tripartite motif-containing 6; tripartite motif-
containing 34 
Rh04256228_m1 316 
TRIM38 Restriction 694861 10475 tripartite motif-containing 38 Rh02860500_m1 127 
TRIM5_3_4 Restriction 574288 85363 tripartite motif containing 5; exon 3-4 junction, all isoforms Rh02788627_m1 
121,31
7 
TRIM5A_7_8 Restriction 574288 85363 tripartite motif containing 5; exon 7-8 junction, alpha isoform only Rh02788631_m1 
121,31
7 
ZC3H12A Restriction 713604 80149 zinc finger CCCH-type containing 12A; MCPIP1 Rh02882632_mH 
139 
CLDND1 Dependency 698472 56650 claudin domain containing 1 Rh01026490_m1  
DMXL1 Dependency 698117 1657 Dmx like 1 Rh02857893_m1  
DNAJB2 Dependency 702936 3300 DnaJ heat shock protein family (Hsp40) member B2 Rh02800276_m1  
FNTA Dependency 712681 2339 farnesyltransferase, CAAX box, alpha Hs00954344_g1  
FYB / ADAP Dependency 693951 2533 FYN binding protein Rh02838822_m1  
KLF2 Dependency 719492 10365 Kruppel like factor 2 Rh02927457_mH  
MAP4 NM Dependency 100423619 4134 microtubule associated protein 4 Rh02841978_m1  
MAP4 XM Dependency 711097 4134 microtubule associated protein 4 Rh02841981_m1  
MED4 Dependency 704644 29079 mediator complex subunit 4 Rh02800666_m1  
MED14 Dependency 699395 9282 mediator complex subunit 14 Rh02847948_m1  
NUP153 Dependency 703888 9972 nucleoporin 153 Rh02856816_m1  
NUP155 Dependency 706019 9631 nucleoporin 155 Rh00897468_m1  
PIP5K1C Dependency 721744 23396 phosphatidylinositol-4-phosphate 5-kinase type 1 gamma Custom  
PSIP1 / LEDGF 
/ p75 Dependency 664733 11168 PC4 and SFRS1 interacting protein 1 Rh02851085_m1  
RANBP1 Dependency 719448 5902 RAN binding protein 1 Rh00862133_g1  
RANBP2 Dependency 694823 5903 RAN binding protein 2; NUP358 Hs01108576_m1  
SLC2A1 / 
GLUT1 Dependency 698931 6513 solute carrier family 2 member 1 Rh02861051_m1  
SLC38A6 Dependency 704017 145389 solute carrier family 38 member 6 Hs01553968_m1  
SPG7 Dependency 699488 6687 SPG7, paraplegin matrix AAA peptidase subunit Custom  
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Table 3.1. (Continued) 
Gene Name Category ENTREZ ID Mm 
ENTREZ 
ID human HGNC Full Name Assay ID Ref 
STK39 Dependency 704855 27347 serine/threonine kinase 39 Rh01085344_m1  
SUN2 Dependency 704914 25777 Sad1 and UNC84 domain containing 2 [Homo sapiens Hs00992164_m1  
UBASH3A Dependency 722456 53347 ubiquitin associated and SH3 domain containing A Custom  
ZNRD1 Dependency 712151 30834 zinc ribbon domain containing 1 Rh01548529_m1  
IFI27 IFN-induced 700513 3429 interferon alpha inducible protein 27 Rh02808321_mH 361 
ISG20 IFN-induced 698376 3669 interferon stimulated exonuclease gene 20 Rh01088632_m1 361 
MX1 IFN-induced 715186 4599 MX dynamin like GTPase 1 Rh02842279_m1 361 
OAS1 IFN-induced 712265 4938 2'-5'-oligoadenylate synthetase 1 Rh00973637_m1 361 
OAS3 IFN-induced 712342 4940 2'-5'-oligoadenylate synthetase 3 Rh02859894_m1 361 
RSAD2 IFN-induced 708720 91543 radical S-adenosyl methionine domain containing 2; Viperin Rh00369813_m1 
361  
CCL20 DEG in HIV 574182 6364 C-C motif chemokine ligand 20 Rh02788116_m1 346 
DUSP4 DEG in HIV 714290 1846 dual specificity phosphatase 4 Rh01027784_m1 346 
FOSB DEG in HIV 715896 2354 
FosB proto-oncogene, AP-1 transcription 
factor subunit Rh02861651_m1 
346 
HLA-DRA / 
MAMU-DRA DEG in HIV 100187587 3122 
major histocompatibility complex, class II, DR 
alpha Rh02621773_m1 
346 
IL12RB2 DEG in HIV 700677 3595 interleukin 12 receptor subunit beta 2 Rh02839111_m1 346 
LDLRAP DEG in HIV 713032 26119 low density lipoprotein receptor adaptor protein 1 Rh02870367_m1 
346 
PECAM1 DEG in HIV 718302 5175 platelet and endothelial cell adhesion molecule 1 Rh02828627_m1 
346 
PIK3IP1 DEG in HIV 716694 113791 phosphoinositide-3-kinase interacting protein 1 Rh02851758_m1 346 
RALGPS2 DEG in HIV 717165 55103 Ral GEF with PH domain and SH3 binding motif 2 Hs01000187_m1 
346 
ZEB2 DEG in HIV 705439 9839 zinc finger E-box binding homeobox 2 Rh02708878_m1 346 
 
 
Acute SIV infection 
Eight Indian-origin rhesus macaques were infected intravenously with 500 TCID50 (50% 
tissue culture infective dose) of SIVmac239. Intravenous infection with a high dose of virus 
ensures a reliable and synchronous take of infection with a well-defined disease course. Four 
animals were sacrificed at day seven post infection and four animals were sacrificed at day 10 
post infection. From previous studies, day 10 post infection is the known peak of plasma viral 
load and SIV gag DNA copies in CD4 memory T cells and was selected to maximize the chance 
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of detecting individual infected cells 163,165. Lymphocytes were isolated from jejunum tissue and 
viably frozen. 
 
Single cell qRT-PCR 
Frozen viable lymphocytes isolated from the jejunums of each of the day 10 post 
infection animals were thawed, stained with antibodies to identify live CD4+ CD95+ memory T 
cells, and sorted using FACS. Using the Fluidigm C1 Single Cell Autoprep system, 
approximately 2000 cells in suspension were flowed through a microfluidic integrated fluidic 
circuit (IFC) with 96 single cell capture sites. Cells were stained with a viability dye and each 
capture site was visualized with a fluorescent microscope to verify the number and viability of 
captured cells. This system then lyses the cells, performs reverse transcription and gene-specific 
pre-amplification, and produces cDNA for each captured cell in nanoliter-scale reaction 
chambers. Output cDNA is then loaded into a Fluidigm BioMark IFC for qRT-PCR of 96 assays 
from each captured cell.  
Jejunum CD4 memory T cells from each of the four day 10 animals were analyzed using 
a total of five C1 capture cycles. Of the possible 96 capture sites, 78 were filled on average for a 
total of 390 cells. A multi-step quality control procedure was used to ensure that each cell 
represented a single live cell. While captured in the C1 chip, cells were stained with live/dead 
dye and manually inspected using a microscope. Wells with more than one cell captured were 
noted and eliminated from downstream analysis. The live/dead status of each cell was also 
recorded. After gene expression analysis, the number of detectable genes expressed by each cell 
was determined, showing clear separation of three populations of cells (Supplemental Figure 
3.1). Empty wells expressing no detectable target genes were eliminated from further analysis. 
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Occasionally, a cell that stained as live failed to have any detectable assays expressed and was 
subsequently classified as an empty well and removed from analysis (8/62 empty wells = 13%). 
This could be due to a technical failure of the RNA isolation or cDNA conversion. A second 
group of cells expressed between four and 20 genes. These cells stained dead or had been 
identified as an empty well 87% of the time and were also removed from downstream analysis. 
A third group of cells expressed more than 20 genes. These cells stained live 90% of the time 
and were considered live, single cells. After quality control metrics were applied, there were on 
average 66 live cells per run for a total of 330 single cells analyzed. 
 
Identification of SIV-infected T cells by single cell transcriptional profiling 
Overall, at least one of the employed SIV RT-PCR assays yielded detectable signal in 
24.5% of the cells. To ensure comparison of truly infected and uninfected cells, we eliminated 
cells expressing only one of the detected SIV transcripts from analysis resulting in 19.9% (61 of 
307) productively SIV-infected live cells. This percentage of SIV-infected jejunal T cells in 
acute SIV infection is in agreement with previously published studies and suggests that the 
freeze/thaw and capture process did not significantly alter the proportion of infected cells 165,180. 
As expected, the spliced Tat-Rev transcript was expressed in the lowest proportion of infected 
cells (25%), while the LTR, R-region, and Gag transcripts were expressed in a higher proportion 
of infected cells (80-95%). 
 
Analysis of single cell gene expression 
Expression of all 89 genes (excluding endogenous control genes) in each of the 307 
uninfected and infected single cells was visualized and cells clustered by similarity using 
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unsupervised hierarchical clustering (Figure 3.1). This analysis places many of the SIV-infected 
cells in close proximity to each other, likely driven by their expression of SIV transcripts. The 
heatmap also shows the expected highly stochastic nature of single cell gene expression 280,362. A 
complementary method of assessing similarity between cells is principal component analysis 
(PCA), a method to reduce the complexity of a high-dimension data set to the most informative 
few dimensions. Via PCA, all 307 cells were clustered based on expression of the 89 genes and 
colored by infection status, clearly demonstrating infected cells clustering separately from 
uninfected cells (Figure 3.2.A. and B.). The loading factors for each axis are also shown (Figure 
3.2. C.-E.) and the SIV assays are major drivers of the separation on all three axis.  
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Figure 3.1. Single cell gene expression from acute SIV infected jejunual CD4+ memory T 
cells identifies individual infected and uninfected cells. 
Heatmap displaying Log2 expression data from 89 genes arrayed horizontally in 307 single cells 
arrayed vertically. Genes and cells were clustered using unsupervised hierarchical clustering with 
Euclidean distance and complete linkage parameters.  SIV-specific assays are outlined in green 
and individual infected cells as defined by at least two SIV assays detected are highlighted in 
green. Grey represents missing data. 
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Figure 3.1. (Continued)
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Figure 3.2. Principal component analysis clusters single cells by infection status.  
Principal component analysis (PCA) was performed based on all 89 genes/assays for 307 single 
cells (A and B). Each symbol represents an individual cell and is colored based on infection 
status. Loading factors for PC1 (C) and PC2 (D) and PC3 (E) are shown with SIV assays 
highlighted in green. 
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Gene expression differences between infected and uninfected cells 
Because not all genes are expressed in all single cells at all times, analysis of differential 
gene expression at the single cell level requires distinct approaches and methods as compared to 
analysis of gene expression in bulk populations of cells. Expression of genes in single cells often 
occurs in transient bursts resulting in stochastic effects that can result in the failure to detect 
expression of a gene at the time of analysis 280,362. Furthermore, despite technical advances in the 
analysis of gene expression in single cells that provide a sensitivity of 1-5 molecules per cell 
363,364, technical limitations of single cell analysis may result in failure to detect target RNAs. 
The net result of both of these factors is zero-inflated data sets, which require distinct approaches 
to deal with the two data components: discrete expression (i.e. the gene is on or off) and 
continuous expression (i.e. for expressed genes, the level of expression). 
Due to zero-inflated data, traditional statistical methods such as t-tests fail to fully 
account for differences between two groups of single cell data sets. Since normal statistical 
distributional assumptions are violated, regular Poisson or negative binomial regression models 
cannot fit the data effectively. To find which individual genes are the most differentially 
expressed, we implemented a zero-inflated Poisson (ZIP) regression approach. Using the ZIP 
model, the top significant differentially expressed genes were CXCR5 (joint p value=0.00083), 
PD-1 (0.0046), Fos (0.011), APOL6 (0.021), and VIM (0.035) (Figure 3.3.A). As a 
confirmation, a very similar published method 365 differing only in choice of joint test (a 
combined likelihood-ratio test) was used, and the results largely agreed, ordering the top four 
genes in the same rank order. 
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 Importantly, uninfected and infected cells did not differ in continuous (Figure 3.3.B) or 
discrete (Figure 3.3.C) expression when all genes in the panel were aggregated. This suggests 
that cells which become infected are not more globally transcriptionally active. 
A complementary method to identify differences between infected and uninfected cells is 
to assess the percent of cells that are infected if they express a certain gene (Figure 3.3.D). For 
example, of the 177 cells expressing detectable CD4 transcripts, 18.8% were infected. The mean 
level of infection for cells expressing any individual cellular gene was 19.6%. Cells that 
expressed CXCR5 were 39.6% infected (the highest of any cellular gene) and cells that 
expressed PD-1 were 34.4% infected (third highest of any cellular gene). Rate ratios were 
calculated for each gene and a negative binomial model was used to calculate 95% confidence 
intervals for outlier analysis. Only CXCR5 and PD-1 were identified as outliers by this method. 
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Figure 3.3. Five genes were significantly differentially expressed in infected as compared to 
uninfected cells using zero-inflated Poisson statistics. 
Expression of the five differentially expressed genes is shown in uninfected and infected cells 
(A). The split violin plot is a smoothed representation of the detected Log2 expression level of 
the individual cells on the y-axis. The left side in blue is comprised of only uninfected cells (zero 
SIV assays detectable), while in red on the right side are infected cells (at least two SIV assays 
detectable). The bar chart displays the proportion of cells in each population that expressed 
detectable levels of the gene. P-values are the odds-ratio for detected expression (non-zero), 
infected vs. uninfected. Overall gene expression did not differ between infected and uninfected 
cells as measured by continuous (B) or discrete expression (C) using paired T-tests. The 
proportion of cells expressing each gene that was infected is displayed (D). Outlier analysis 
identified CXCR5 and PD-1 as significant (after removal of SIV assays). Colors represent the 
category of gene, and an X symbol represents a gene that has been reported to be type I 
interferon-inducible. 
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Figure 3.3. (Continued) 
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Characterization of a novel cell population discovered through single cell expression analysis 
Both statistical approaches described above identified CXCR5 and PD-1 as highly 
differentially expressed genes between infected and uninfected cells. Together CXCR5 and PD-1 
are markers for T follicular helper cells (Tfh), 152 and both genes were enriched in the proportion 
of infected cells expressing them as compared to uninfected cells. Additionally, CXCR5 and PD-
1 were coexpressed in the same uninfected single cell 3.7% of the time compared to 19.7% in 
infected cells, a significant enrichment as assessed by Fisher’s exact test (p=0.0006).  
These markers, especially if expressed in combination, suggest the presence of a distinct 
subpopulation of CD4 T cells that is infected at a high rate in acute SIV infection. The presence 
of Tfh cells in jejunum has not been previously described, however. To determine the presence, 
frequency, and cell surface phenotype of cells expressing CXCR5 and PD-1 in cells derived from 
jejunum, we used a 14-color flow cytometry panel (Figure 3.4.A). The existence of a CXCR5+ 
PD-1+ population of memory CD4+ T cells in the jejunum of uninfected animals was confirmed. 
The population is similar to that seen in spleen or lymph node although lower in frequency, and 
this population is absent from peripheral blood (Figure 3.4.B).  
After verifying the existence of a PD-1+ CXCR5+ population of memory CD4+ T cells 
in jejunum, phenotypic markers characteristic of Tfh cells were analyzed in comparison to the 
same population from spleen or lymph node. Jejunum, spleen, and lymph node PD-1+ CXCR5+ 
cells expressed comparable levels of ICOS (CD278) and CD69 (Figure 3.4.C). The level of both 
markers was higher than that in the bulk CD95+ memory CD4+ T cells from each compartment. 
Both proteins are known to be enriched in Tfh cells 366,367. Jejunum and spleen PD-1+ CXCR5+ 
cells also expressed similar levels of a characteristic Tfh marker CD200 as well as CTLA4 
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(Figure 3.4.C), again at higher levels than the bulk CD95+ CD4+ T cells. CD200 is a marker of 
Tfh cells that is very specific to these cells 271.  
Since CCR5 is the primary coreceptor for SIVmac and most transmitted HIV-1 strains 
29,30,173, the level of expression of CCR5 could reflect the susceptibility of individual cells to 
infection. Similar to PD-1+ CXCR5+ T cells from spleen and lymph node, the PD-1+ CXCR5+ 
population in jejunum expressed low levels of CCR5 (Figure 3.4.D). The PD-1mid CXCR5neg 
population expressed the highest CCR5 levels in each tissue of the tested populations.  
The only phenotypic difference found between jejunum and spleen PD-1+ CXCR5+ cells 
was increased CCR7 expression in jejunum. This was despite generally lower CCR7 expression 
in jejunum total CD4+ T cells (Figure 3.4.E), consistent with lower expression of CCR7 on T 
cells from extralymphoid locations compared with the spleen. 
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Figure 3.4. PD-1+ CXCR5+ cells from SIV-uninfected jejunum exhibit phenotypic 
characteristics of Tfh cells. 
The gating strategy for phenotypic analysis of PD-1 and CXCR5 cell populations and example 
histograms showing expression of phenotypic markers in the PD-1+ CXCR5+ population as 
compared to total CD4+ T cells is shown (A). The frequency of PD-1+ CXCR5+ cells as a  
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Figure 3.4. (Continued) 
percentage of total CD95+ memory CD4+ T cells in various anatomical locations is shown (B). 
The numbers above each location represent the mean of 4-5 animals. The MFI of surface 
markers typically found on Tfh cells is shown for cells from jejunum, spleen, and axial lymph 
node from four animals (C). The MFIs of CCR5 in defined populations of CD4+ T cells from 
jejunum, spleen, and lymph node are shown (D). The MFIs of CCR7 in defined populations of 
CD4+ T cells from jejunum and spleen are shown (E). 
 
A defining characteristic of Tfh cells is the expression of the transcription factor BCL6 
257. Using intracellular staining and flow cytometry, a similar level of BCL6 protein expression 
was found in jejunum PD-1+ CXCR5+ cells as in the corresponding population in spleen and 
lymph node (Figure 3.5.A). The primary cytokine produced by Tfh cells critical for their 
function is IL-21 152. Production of IL-21 mRNA is significantly higher in sorted PD-1+ 
CXCR5+ cells compared to other sorted subsets (Figure 3.5.B). 
 
  
 
Figure 3.5. Functional characterization of PD-1+ CXCR5+ cells shows Tfh characteristics. 
Intracellular staining for BCL6 protein in jejunum, spleen, and lymph node populations is 
displayed as mean fluorescent intensity (A). Each point represents an individual sample. The 
expression of IL-21 mRNA in sorted populations of PD-1 and CXCR5 cells compared to CD95- 
CD28mid naïve CD4+ T cells (B). p< 0.0001 by paired T test for each comparison with the PD-1+ 
CXCR5+ population. 
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High-throughput gene expression profiling 
Analysis of Tfh phenotypic markers and BCL-6 protein expression suggested that the 
PD-1+ CXCR5+ memory CD4+ T cell population from jejunum was similar to that of Tfh cells 
found in spleen or lymph node. To better assess the potential similarity of these populations, a 
panel of 77 Tfh-associated genes was identified. Genes were selected that were known to be 
enriched in Tfh cells such as IL-4 and IL-21, or decreased in Tfh cells such as IL-4R and GATA3. 
Using RNA-Seq data from a recent publication 276, template matching 368 was used to discover 
additional, less well known, Tfh genes. We utilized the published RNA-Seq data from four 
sorted populations of cells: bulk CD4+ T cells, Tfh cells (CXCR5+PD1hiCD127-CD25-), T 
follicular regulatory cells (TfhR) (CXCR5+PD1hiCD127-CD25+), and T regulatory cells 
(CXCR5+/-PD1lo/intCD127- CD25+). Template matching is an algorithm that ranks the expression 
profile of each gene for its correlation to a predefined template. In this case, we sought to find 
genes whose expression was high in Tfh cells while low in the other three cell populations, or 
high in Tfh and TfhR cells while low in the other two. As for any correlation measure, the output 
is an R- and P-value for each gene. The entire list of over 10,000 expressed genes can be ranked 
by R-value, ordering the genes that best match the template (for example, high expression in Tfh 
and low in other cells) with the highest R-value to the genes that least match the template with 
the lowest R-value. This allowed for an unbiased selection of the most differentially expressed 
genes between Tfh cells and other CD4+ T cells. Markers classically associated with Tfh cells 
such as CD200, PD-1, and BCL6 all ranked in the top 30 genes, validating the method. 
To analyze the similarity of gene expression in jejunum PD-1+ CXCR5+ cells and 
classical Tfh cells, the following PD-1 and CXCR5 memory CD4+ T cell populations were 
sorted from jejunum and axial lymph node: PD-1+ CXCR5+, PD-1mid CXCR5-, and PD-1- 
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CXCR5-, as well as CD95- CD28mid naïve CD4+ T cells. In addition, cells using a common 
definition for Tfh, memory CD4+ T cells expressing PD-1 and CD200, were sorted, and gene 
expression was measured for all 77 genes in the panel. Expression was normalized to ACTB, the 
most stable control gene as determined by the NormFinder algorithm 319. Using unsupervised 
hierarchical clustering, a clear group of PD-1+ CXCR5+ cells from jejunum, PD-1+ CXCR5+ 
cells from axial lymph node, and PD-1+ CD200+ cells from lymph node was found (Figure 3.6) 
demonstrating their similar expression of over 77 Tfh-related genes. Naïve CD4+ T cells also 
segregated together, while the PD-1mid CXCR5- and PD-1- CXCR5- populations showed 
intermediate expression of many Tfh-related genes. Some differences were attributable to the 
tissue of origin. For example, lower CCR7 and KLF2 expression in lymph node cells. However, 
these differences were smaller than those between the sorted populations. SIV infection status of 
the animals did not affect the overall clustering of cells by PD-1 and CXCR5 surface phenotype 
since samples from infected and uninfected animals were interspersed in the major clusters. 
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Figure 3.6. The expression profile of PD-1+ CXCR5+ cells from jejunum clusters with that 
of Tfh cells from lymph nodes. 
Sorted subpopulations of PD-1/CXCR5 memory CD4+ T cells as well as naïve cells were 
examined for expression of a panel of 77 genes that exhibited significant differential expression 
in Tfh cells as compared to bulk CD4+ T cells or Treg cells. Normalized results are displayed 
using unsupervised hierarchical clustering. Samples are coded for cell population, tissue of 
origin, and infection status using color bars under the sample names. 
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Principal component analysis with all 77 genes also tightly grouped PD-1+ CXCR5+ 
cells from jejunum with PD-1+ CXCR5+ cells from axial lymph node and PD-1+ CD200+ 
defined Tfh cells from axial lymph node (Figure 3.7.A). As shown by the loading factors, the 
clear separation on the PC1 axis is driven by genes known to be enriched in Tfh cells such as 
IL21, as well as genes known to be decreased in Tfh cells, such as IL4R and IL7R, thus 
demonstrating the Tfh-like characteristics of the PD-1+ CXCR5+ population (Figure 3.7.B). 
Importantly, clustering was primarily based on cell subset, not tissue location or infection status 
of the cells. The tight similarity of the PD-1+ CXCR5+ cells to Tfh cells from lymph nodes in 
the expression of 77 genes strongly suggests these cells are also Tfh cells. 
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Figure 3.7. Principal component analysis clusters PD-1+ CXCR5+ cells from jejunum with 
Tfh cells. 
Using the panel of 77 Tfh-related genes, PCA was used to cluster each sorted subset of PD-1 and 
CXCR5 memory CD4+ T cells or naïve cells from both axial lymph nodes and jejunum (A). 
POP1 = PD-1+ CXCR5+, POP2 = PD-1mid CXCR5-, POP3 = PD-1- CXCR5-, and naïve = 
CD95- CD28mid. The genes that were the strongest drivers of differentiation on the PC1 axis are 
displayed as loading factors (B). They included genes with known high expression in Tfh cells 
like IL21 and CD200 as well as genes with known low expression in Tfh cells like CCR7 and 
IL7R. 
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Acute SIV infection reveals high susceptibility of PD-1+ CXCR5+ cells 
 Populations of CD4+ T cells were sorted from jejunum of SIV infected rhesus macaques 
at either seven or 10 days post infection. As before, the sorted populations were naïve (CD28mid 
CD95+) and memory CD95+ cells from PD-1+ CXCR5+, PD-1mid CXCR5-, and PD-1- 
CXCR5-  subpopulations. After DNA/RNA extraction, the levels of SIV Gag DNA and RNA 
were quantified in comparison to standard curves of known concentrations (Figure 3.8A and B). 
At 10 days post infection, the PD-1+ CXCR5+ population had the highest level of SIV Gag 
DNA (mean of 3.41 copies/cell) and RNA (mean of 228 copies/cell), substantially more than any 
other population. Strikingly, the PD-1+ CXCR5+ population is more highly infected than the 
PD-1mid CXCR5- population which expressed higher levels of the SIV coreceptor CCR5 
surface protein (Figure 3.4.D) and mRNA (Figure 3.6). Levels of SIV Gag DNA and RNA were 
much lower for animals at seven days post infection, with only one of the four animals having 
detectable virus in all four cell populations (data not shown). 
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Plasma viral loads were measured for all eight animals using quantitative RT-PCR 354,355. 
When compared to the animals with detectable SIV gag DNA in the PD-1+ CXCR5+ jejunal 
cells, a positive relationship emerged, although it did not reach significance (p=0.07, Spearman 
correlation), likely due to the relatively small sample size. This suggests that plasma viral load is 
reflective of tissue viral burden. Similarly, a non-statistically significant positive relationship was 
found between the SIV gag DNA copies per cell in the PD-1+ CXCR5+ population and the 
 
Figure 3.8. PD-1+ CXCR5+ cells from jejunum are highly susceptible to acute SIV 
infection. 
Memory CD4+ T cells were sorted and the Gag DNA copies per cell were quantified by qRT-
PCR with a standard curve (A). Gag RNA copies from the same cell populations were also 
quantified (B). Plasma viral load (C) and the percent of single cells that were infected (D) show 
positive relationships with the total Gag DNA copies from the PD-1+ CXCR5+ memory CD4+ 
T cell population. 
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percent of cells that became infected at a single cell level in the day 10 post infection animals. 
This suggests that the single cell capture and processing did not bias selection of infected cells.  
 Overall, single cell gene expression measurements identified a subpopulation of memory 
CD4+ T cells that are highly susceptible to acute SIV infection in vivo. These cells were further 
characterized to have many phenotypic, transcriptional, and functional features of Tfh cells 
despite their localization in jejunum tissue, where Tfh cells have not been previously described.  
 
3.E. Discussion 
A complete molecular description of an in vivo target cell for immunodeficiency virus 
infection is currently lacking. Traditional gene expression measurements that average expression 
from multiple cells may overlook critical subpopulations. Through the use of single cell qRT-
PCR, memory CD4+ T cells from acute in vivo SIV-infected rhesus macaque mucosal tissue 
were analyzed for the expression of genes predicted to distinguish why certain cells became 
infected. Individual infected and uninfected cells were identified through qRT-PCR of multiple 
SIV sequences, and the level of infection averaged 20%. Lineage markers PD-1 and CXCR5, 
with nearly 20% of infected cells expressing both genes compared to just 3.7% of uninfected 
cells, were the most differentially expressed genes. These cell surface proteins can define Tfh 
cells; however, existence of a PD-1+ CXCR5+ population in jejunum had not previously been 
described. A reproducible population with a frequency intermediate to that in peripheral blood 
and lymph node was found to exist in jejunum and expressed cell surface molecules 
characteristic of Tfh such as ICOS, CD69, CTLA4, CCR5, and CD200. In addition, the jejunal 
PD-1 CXCR5+ population expressed the canonical Tfh transcription factor BCL6 at similar 
levels to those observed in classical Tfh populations from lymph node or spleen. Additionally, 
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the expression profile of over 70 Tfh-associated genes in the PD-1+ CXCR5+ cells from jejunum 
was remarkably similar to classical Tfh cells. Finally, the PD-1+ CXCR5+ cells from jejunum 
were found to be highly SIV-infected, with an average of over three SIV DNA copies/cell at 10 
days post infection. 
 Gene expression at the single cell level, even among phenotypically identical cells, can 
vary widely due to both intrinsic (reactions involving small numbers of molecules are dominated 
by large concentration fluctuations and inherently noisy) 369 and extrinsic (microenvironment) 
factors 277. Overcoming noise at the single cell level is possible by analyzing relatively large 
numbers of genes in tens to hundreds of cells, a process that is facilitated by instrumentation for 
high-throughput transcriptional profiling 278. Using single cell qRT-PCR, it is possible to dissect 
heterogeneous tissues into cell subpopulations according to their unique gene expression profiles 
and uncover rare cell populations that may be hidden in bulk analysis 370-372. Additionally, 
studies at the single cell level have shown that the noise or variation in protein levels is primarily 
predicted by variation in mRNA levels 373-375. Therefore, measuring mRNA is an accurate proxy 
for protein levels in most cases, even in single cells. 
 Very few studies have measured viral infection at the single cell level 376, and fewer have 
measured cellular gene expression in single infected and uninfected cells. The only in vivo single 
cell viral infection study published to date used rotavirus to infect mice and measured gene 
expression in purified, sorted single intestinal epithelial cells (IECs) by qRT-PCR 377. This 
method accounts for possible differences between directly infected cells and bystander cells, 
while bulk analysis is generally unable to distinguish the two (for example, comparing bulk cells 
from infected and uninfected animals). Although the population of IECs was homogenous based 
on surface marker expression, considerable heterogeneity was found in response to virus in both 
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virus-infected and bystander cells. The authors speculated that different physical position along 
the crypt-villus and proximal-distal axes plus distance from regulatory non-epithelial cells such 
as dendritic cells could result in different microenvironments and therefore different 
transcriptional responses to infection. The pre-sorting of cells for populations infected at higher 
(CD26+, 200-fold increased infection) and lower rates (CD44+ crypt cells, resistant to infection), 
while necessary for obtaining sufficient virally infected cells, did not allow for determining 
differences in each subpopulation’s susceptibility to infection or the frequency of infection. 
Additionally, the study focused on the subversion of the interferon response by rotavirus and 
accordingly selected a panel of genes related to interferon. Here we took advantage of the very 
high level of infection within mucosal memory CD4+ T cells during acute SIV infection 165 to 
avoid biasing the cell selection and used a panel of genes predicted to influence cell 
susceptibility to infection. This approach allowed for discovery of an undescribed subset of cells 
harboring high levels of virus. 
 Classical T follicular helper cells (Tfh) are a CD4+ helper T cell subset specialized for 
providing help for B cells 152. They are essential for germinal center formation, affinity 
maturation, and class-switch recombination, and allow the formation of antibody-producing 
plasma B cells and long-lived memory B cells via their expression of CD40 ligand, IL-21, IL-4 
and other molecules. ICOS expression is important for Tfh differentiation, migration into 
follicles, and functions 248,253,378. Similar levels of ICOS expression were seen in the PD-1+ 
CXCR5+ cells from jejunum with spleen and lymph node Tfh cells in this study. Tfh 
differentiation requires expression of the transcription factor BCL6 251,256,379. BCL6 expression 
likely promotes Tfh differentiation by multiple mechanisms that have not been fully described. 
However, it is known to repress Blimp-1 256 as well as Th1, Th2, Th17, and Treg transcription 
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factors, and cytokine genes 251,257. Here we demonstrated that BCL6 protein and transcript 
production in PD-1+ CXCR5+ cells from jejunum reaches similar levels as Tfh cells from lymph 
node and spleen.  
The first reports characterizing Tfh cells were in tonsil lymphoid tissue 366,380, and much 
of the Tfh research to date has focused on secondary lymphoid tissue, particularly those in 
germinal centers. More recently, Tfh-like cells have been found in peripheral blood that express 
CXCR5 and share functional properties with Tfh cells, including secretion of IL-21 and 
induction of naïve B cell proliferation, differentiation, and class-switching (reviewed in 381,382). 
These circulating Tfh cells do not express BCL6 protein and express relatively low levels of 
activation markers like ICOS and CD69. Subsets of circulating Tfh cells do express the 
cannonical transcription factors for Th1 (T-bet), Th2 (Gata3), and Th17 (RORγt) cells. Here we 
show that the PD-1+ CXCR5+ cells from jejunum express BCL6 protein and activation markers 
at comparable levels to Tfh cells from lymph nodes, and do not express T-bet, Gata3, or RORγt 
(Figure 3.6), thus distinguishing this population from circulating Tfh cells. 
Though similar to classical germinal center Tfh cells in many phenotypic and 
transcriptional respects, the jejunum PD-1+ CXCR5+ population described here differs by 
expressing higher levels of CCR7 (Figure 3.4.E and Figure 3.6). A study found that CXCR5 
overexpression was not sufficient to promote follicular entry of naive T cells unless the 
counterbalancing CCR7 expression was reduced 383. This, along with the lack of organized 
lymphoid structures, suggests that the jejunum PD-1+ CXCR5+ cells do not reside in organized 
follicles. Additionally, localization of Tfh to follicles is aided by GPR183/EBI2 expression, 
while final localization to germinal centers requires reduction of GPR183 expression 384. Here 
we show Tfh cells from lymph nodes expressed lower levels GPR183 compared to the jejunum 
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PD-1+ CXCR5+ cells (Figure 3.6). A final indication that these cells are not likely to be located 
in germinal centers is their differential expression of SH2D1A/SAP compared to Tfh cells from 
lymph nodes (Figure 3.6). In the complete absence of SAP, Tfh cells have defective adhesion to 
GC B cells and fail to be retained in GCs, and loss of SAP leads to complete loss of germinal 
center Tfh cells and germinal center B cells 385. Here the jejunum PD-1+ CXCR5+ cells do 
express SAP, but at lower levels than Tfh cells from lymph nodes.  
Peyer’s patches, lymph nodes located primarily in the distal ileum 386, have been known 
to harbor Tfh cells 387,388. Only limited recent evidence suggests Tfh or Tfh-like cells can exist 
outside of classically defined immune inductive sites in the mucosa. Mycobacterium 
tuberculosis-specific PD-1high cells residing in the lung parenchyma required intrinsic Bcl6 and 
ICOS expression for their generation, and a fraction of these cells co-expressed CXCR5 351. In a 
humanized-DRAG mouse model, human Tfh cells were found in gut lamina propria at about 1/3 
the frequency of that in Peyer’s patches or mesenteric lymph nodes 352. Here we describe Tfh-
like cells in rhesus macaque jejunum, a site devoid of organized lymphoid tissue. The precise 
function of the jejunum PD-1+ CXCR5+ cells and whether they are tissue-resident or transiting 
between lymph nodes remain to be investigated. 
It is well established that follicles are major sites of HIV 266-269 and SIV 266,270 replication 
and that Tfh cells are targets for HIV and SIV infection 265. One mechanism of enhanced 
follicular replication could be the lack of CD8+ cytotoxic lymphocytes (CTLs) in follicles, as 
this concentrated replication does not exist in acute infection prior to the CTL response 270 or 
after CD8 depletion 271. A previous study failed to find PD-1high cells in jejunum during chronic 
SIV infection 350. The high level of SIV DNA and RNA in the extra-follicular PD-1+ CXCR5+ 
population during acute infection shown here suggests these cells could be depleted early in SIV 
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infection. A recent study bolsters this view, having shown depletion of splenic Tfh cells in acute 
SIV infection of rhesus macaques 272. Alternatively, if these cells migrate to lymph node follicles 
they could be protected from CTL-mediated killing and potentially seed a latent reservoir 271. 
The PD-1+ CXCR5+ jejunum cells described here express lower levels of CCR5 than do 
the PD-1mid CXCR5- population (Figure 3.4.D), yet are infected at a much higher rate (Figure 
3.8.A and B). The vast weight of evidence points to activated, memory CD4+ T cells that express 
CCR5 as the preferred cellular target for HIV and SIV infection 166,389,390. In addition to infection 
studies, most transmitted founder viruses use CCR5 as a coreceptor 173, while CXCR4 usage 
generally only develops later in infection 32. Like HIV-1, SIVmac primarily uses CCR5 as a 
coreceptor 30. Although much evidence points to the importance of CCR5 in viral entry, it has 
been established that Tfh cells from germinal centers, which express low levels of CCR5, are 
found to be infected by HIV and SIV 265,391.  
Some studies have described infection in memory CD4+ T cells that do not express very 
high surface levels of CCR5 yet are infected as measured by SIV DNA 165. Our findings here are 
in agreement with Mattapallil et al.: while CCR5 surface protein expression was low and similar 
to naïve cells, CCR5 mRNA expression was greater in the PD-1+ CXCR5+ population than in 
naïve cells (Figure 3.6). How these cells are infected despite low CCR5 surface expression 
remains to be discovered. Possibilities include a requirement for only a low level of CCR5 
expression, or the cells becoming infected while expressing higher levels of CCR5 and later 
decreasing surface expression. Tfh precursor cells (CXCR5- CD4+ T cells) in lymph nodes 
express higher levels of CCR5 before entering germinal centers, and this has been proposed as 
the point at which Tfh cells become infected 391. Alternative coreceptor usage is another 
possibility. However, in pigtail macaques, Tfh cells from lymph node and spleen were found to 
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express low levels of CCR5 and the alternative SIV coreceptors CXCR6 and GPR15, yet were 
found to be highly infected early in pathogenic SIV infection 392.  
The level of infection in the PD-1+ CXCR5+ population is very high at 3.4 copies of SIV 
Gag DNA per cell on average. Mattapallil et al. measured 1.5 SIV Gag DNA copies per cell in 
bulk memory CD4+ T cells from rhesus macaque jejunum on day 10 post infection 165. The 
highest level of infection in specific CD4+ T cell subsets reported to date during acute SIV 
infection showed a similar level of infection to what we observed in α4+β7high memory T cells in 
peripheral blood at 10 days post infection in SIVmac251-infected rhesus macaques 340. 
Overall, single cell gene expression analysis of individual infected and uninfected cells 
revealed a novel population of PD-1+ CXCR5+ memory CD4+ T cells in rhesus macaque 
jejunum that have many phenotypic and transcriptional similarities to Tfh cells. 
 
Chapter 4: Conclusions and Discussion 
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4.A. Conclusions  
The second chapter in this thesis measured gene expression of putative and confirmed 
restriction and dependency factor genes in defined subsets of CD4+ T cells from peripheral 
blood and jejunum of rhesus macaques. Since memory CD4+ T cells, and specifically those 
expressing CCR5, are particularly susceptible to HIV and SIV infection, we sorted CD4+ T cells 
into defined memory subsets, including CCR5+ cells, and found an overall increase in 
dependency factors in all memory subsets relative to naïve CD4+ T cells. The upregulation of 
genes that are required for SIV replication (dependency factors) in memory CD4+ T cells may 
contribute to the increased susceptibility of this population to SIV infection relative to naïve 
CD4+ T cells. Memory differentiation dynamically modulated expression of restriction factors 
resulting in both upregulation and downregulation of restriction factors. For both restriction and 
dependency factors the expression patterns of those groups of genes alone were sufficient to 
cluster memory subsets together using principal component analysis, demonstrating a 
reproducible pattern of expression due to memory differentiation. Stimulation of CD4+ T cells 
with either anti-CD3/CD28 or type I interferon also led to modulation of expression of restriction 
factors. However, the patterns of modulation following these stimulation modalities did not 
mirror those observed in the process of memory T cell differentiation.  
CD4+ T cells from the intestinal mucosa are the primary target cells in acute SIV and 
HIV infection and are infected at relatively high levels and depleted rapidly, demonstrating that 
they are much more susceptible to infection than cells from peripheral blood. Prior to these 
studies, there was no information on differences in gene expression of restriction and 
dependency factors in CD4 T cells found in peripheral blood or mucosal sites, in large part 
because this gastrointestinal lymphoid tissue, especially in the small bowel, is difficult to sample 
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in humans. We measured gene expression in the same naïve and memory CD4+ T cell subsets 
from jejunum cells and found overall similar patterns due to memory differentiation, which also 
allowed clustering similar to peripheral blood. Despite the broad similarity, there was a 
significant decrease in the average expression of all restriction factors in the CCR5+ memory 
CD4+ T cells from jejunum relative to the same subset from peripheral blood. We suggest that 
this difference may correspond to their increased susceptibility to infection. Finally, acute 
infection with pathogenic SIVmac239 verified that the jejunum CCR5+ memory CD4+ T cells 
had the highest level of cell-associated viral RNA of all memory subsets in acute SIV infection, 
and that infection was associated with a broad increase in expression of nearly all restriction 
factors measured. 
The third chapter in this thesis sought to measure potential gene expression differences at 
a single cell level in CD4+ T cells from the intestinal mucosa during acute SIV infection. Over 
300 single cells were analyzed for the expression of 96 genes and the presence of SIV RNA 
transcripts indicating infection. Comparing the approximately 20% of T cells that were infected 
to uninfected T cells using multiple statistical methods revealed PD-1 and CXCR5 as the most 
differentially expressed genes, with both significantly enriched in infected cells. Expression of 
both PD-1 and CXCR5 can define Tfh cells, however the jejunum lacks the organized secondary 
lymphoid sites where classical germinal center Tfh cells are typically found. Using flow 
cytometry, we verified the existence of a PD-1+ CXCR5+ memory CD4+ T cell population in 
jejunum, which was observed at significantly higher frequencies than peripheral blood but at 
lower levels than that in spleen or lymph node. This population expressed cell surface markers 
typical of Tfh cells (ICOS, CD69, CTLA4, and CD200) as well as the canonical Tfh 
transcription factor BCL6 in similar proportion to Tfh cells from spleen or lymph nodes, 
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distinguishing it from less-activated circulating Tfh cells. To confirm the Tfh-like identity of the 
PD-1+ CXCR5+ population from jejunum, we developed a panel of 77 Tfh-associated genes and 
showed remarkable similarity in expression profiles between this subset and classical Tfh cells 
from lymph nodes. The PD-1+ CXCR5+ population from jejunum was found to be highly SIV-
infected by cell-associated DNA and RNA, with an average of over three SIV DNA copies/cell 
at 10 days post infection. 
 
4.B. Restriction and dependency factor gene expression 
Combinatorial effects of restriction factors 
While study of individual genes is critical for determining their relative contributions and 
mechanism(s) of restriction, the impact of restriction factors on viral replication is likely 
cumulative, since they act on different steps of the viral replication cycle to impair replication. 
Two prior studies have set out to undertake a comprehensive analysis of HIV restriction factors 
in CD4+ T cells. The first measured expression of 34 potential restriction factors in elite 
controllers as compared to untreated non-controls, cART suppressed, and uninfected individuals 
285. They found that the cumulative fold-difference in restriction factor expression with respect to 
a control individual was positively correlated with CD4+ T cell activation, viral load, and the 
expression of ISG15, which is a marker of interferon exposure. These data support our 
conclusions that memory CD4+ T cells, which are more activated than naïve, express generally 
higher levels of restriction factors. Drawbacks to this study include the measurement of 
restriction factor expression only in peripheral blood, which harbors very few infected cells in 
chronic infection, and the use of total CD4+ T cells. Here we showed significant differential 
modulation in naïve and memory subsets, demonstrating that analysis of bulk CD4+ T cells does 
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not accurately reflect the actual target cells for HIV infection. A second study from the same 
group measured expression of 32 restriction factors longitudinally in six untreated HIV-infected 
patients starting approximately 10 weeks post infection and up to seven years 286. Similarly, they 
found that restriction factor expression significantly associated with systemic CD4+ T cell 
activation and viral load. Their study lacked acute phase measurements and also did not 
differentiate among CD4+ T cell subsets. The authors speculated that a general increase in 
restriction factor expression could be due to viral infection and depletion of cells expressing 
lower levels of restriction factors, but this conclusion is hard to verify without analyzing 
expression in specific CD4+ T cell subsets. Our post-infection data shows that memory subsets, 
despite expressing relatively higher levels of restriction factors than did naïve, become infected 
at a higher rate, so restriction factor expression levels alone are unlikely to explain differential 
susceptibility. 
Tissue differences in gene expression 
 No study published to date has measured either restriction factor expression in CD4+ T 
cells from the intestinal mucosa or restriction factor expression during acute infection. The initial 
target cells of most human HIV infections are located at mucosal sites, yet potential tissue 
differences have been understudied due to limited accessibility in humans. Mucosal CD4+ T 
cells are particularly susceptible to infection and are depleted early in both acute SIV and HIV 
infection. One hypothesis proposed to explain this observation is the higher proportion of 
memory cells (and especially CCR5-expressing cells) than naïve in mucosal sites, which we also 
observed by flow cytometry. Another possibility is a higher proportion of “activated” cells. 
Although cellular activation has multiple definitions, a predicted phenotype of activated cells 
would be generally higher levels of transcription. The non-normalized Ct data for equal cell 
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equivalent inputs from peripheral blood and jejunum in the same subset did not significantly 
differ. For example, the mean Ct was 18.6 in peripheral blood TM, which is slightly higher 
expression than the mean Ct of 18.9 in jejunum TM cells across 182 expressed genes. Since we 
did not see evidence of overall increases in transcription in tightly defined populations of 
memory cells in jejunum compared to peripheral blood, the observed increase in activation 
between tissues may mainly reflect the differing proportions of memory subsets. It is possible 
that overall transcription is not the best measure of activation and that some other aspect of 
activation underlies tissue differences, or that cell processing altered the true in vivo conditions. 
 In light of their importance in HIV acquisition and pathogenesis, there has been 
significant interest in designing an HIV vaccine that prevents infection at mucosal sites 
(reviewed in 393). Expression of restriction factors has correlated with reduction of viremia in 
IFN-α treatment in vivo in both humans and macaques 203,206, expression of the likely restriction 
factor SLFN11 correlated with elite control 285, and higher basal expression of TRIM5α 
correlated with resistance to repeated low dose SIV challenge 394, cumulatively suggesting a 
mechanism in which increased expression of restriction factors could inhibit infection. Future 
vaccine or adjuvant studies could measure restriction factor expression to determine if expression 
can be induced by vaccines, how durable induction is, and if expression of restriction factors 
correlates with protection. 
Post-infection restriction factor expression 
 At the peak of acute SIV infection, expression of many restriction factors was increased 
compared to uninfected animals in both peripheral blood and jejunum, suggesting systemic 
modulation of expression in multiple compartments. While known interferon-stimulated genes 
increased the most during infection, other non-ISGs also exhibited altered expression; therefore, 
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it is likely cytokines/chemokines in addition to interferon play a role in vivo. The largely 
unknown mechanisms of interferon-independent control of restriction factor expression could 
have important implications, for example in vaccine/adjuvant design. 
 Interestingly, the fact that transitional memory (TM) CCR5+ CD4+ T cells from jejunum 
expressed relatively lower levels of restriction factors than the same cells from peripheral blood 
also held true at 10 days post infection (data not shown). Cells from jejunum were more highly 
infected than peripheral blood, yet the jejunum TM cells still expressed lower levels of 
restriction factors relative to TM cells in peripheral blood. This suggests that the level of SIV 
infection of specific CD4+ T cell subsets is not the major driver of changes in expression of 
restriction factors, and that other cell types such as dendritic cells may be the source of the 
cytokine cascade known to occur in acute infection 199 that could drive increased expression of 
restriction factors. 
 
4.C. Single cell expression profiling 
Single cell expression technologies  
A number of factors led to the selection of qRT-PCR for single cell expression analysis 
used for these studies. qRT-PCR allows for high-throughput, highly quantitative, and precise 
gene expression measurements with a wide dynamic range of 6-8 orders of magnitude, 
significantly wider than microarray based systems 325. In addition, the specificity of the 
primer/probe real-time PCR assays permits discrimination of specific transcript isoforms. The 
reasonable per-cell cost allows for measurement of hundreds of cells, which is necessary for 
obtaining a sufficient number of infected cells to perform comparative analysis.   
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A drawback to qRT-PCR is that target genes must be selected prior to analysis and that 
assay throughput is limited. Microarrays are a genome-wide technology that provide a more 
comprehensive analysis of gene expression. At the time we began this work, microarrays from 
single cells were technically possible 395-397. However, the large amount of pre-amplification 
necessary to generate sufficient cDNA from a single cell could lead to significant bias, and the 
sensitivity, specificity, and flexibility of microarrays is inferior to qRT-PCR 277. For example, a 
published method for single cell microarrays consists of 30 total cycles of PCR amplification 
prior to array hybridization 396. Splitting the cDNA from a single cell to 96 individual reaction 
chambers in a BioMark IFC also requires pre-amplification. However, to ensure a single mRNA 
is distributed into each chamber, a minimum of 12 cycles are required, and 18 has been shown to 
be reliably sufficient 363. Gene specific pre-amplification as used in microfluidic qRT-PCR is 
also less likely to generate non-specific amplification as shown by the need for an exonuclease 
step in microarray amplification 396. In addition, the high per-cell expense would limit 
throughput of cells, limiting statistical power. 
More recently, single cell RNA sequencing (scRNAseq) has become a popular tool for 
estimating gene expression by counting reads aligning to a coding region of a gene 398,399. 
Benefits to this technology include potential transcriptome-wide coverage and the ability to 
detect microRNAs, splice variants, and uncharacterized transcripts. The initial scRNAseq 
publication performed a comparison with single cell microarrays and found 75% more reads and 
over a thousand unknown splice junctions 398. Despite these potential advantages, technical 
challenges at the time this project was started prevented use of this technology as did a number 
of significant inherent drawbacks. As with microarrays, significant amplification of cDNA is 
required that introduces bias and non-specific products, such that findings using microarray or 
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RNAseq generally require validation by qPCR or in situ hybridization staining 277. The published 
and commercially available methods for reverse transcription and barcoding required for 
scRNAseq rely on poly-T priming 400,401, and therefore would not detect non-poly-adenylated 
viral sequences (for example, the abortive R-region transcripts seen in latently HIV infected cells 
402). The per-cell cost for scRNAseq is at least double that of single cell qRT-PCR, and data 
analysis is much more complicated. Finally, the sensitivity of qRT-PCR in the Fluidigm Biomark 
system has been shown to be able to distinguish a 1.25 fold difference in relative quantity 403 
with a limit of detection of a single mRNA transcript 363, metrics which scRNAseq likely cannot 
match since it has been estimated that about 10 transcript copies per cell cannot be distinguished 
from noise 404. 
Single cell expression of ISGs 
 An interesting observation in the single cell gene expression data was an enrichment of 
detection of type I interferon-stimulated gene expression in infected single cells compared to 
uninfected cells (Figure 3.3.D). The median rank of type I ISGs is 23 of out 85 cellular genes 
based on discrete expression, including seven of the top 10 genes. For example, a cell that 
expresses detectable oas1 was determined to be infected 34.6% of the time compared to a 20% 
average for any given gene, and just missed significance as an outlier (p=0.08). On average, all 
ISG genes increased expression as measured by both discrete and continuous expression in 
infected compared to uninfected cells. Since infected cells but not uninfected bystanders from the 
same tissue increased expression of ISGs (but not overall expression, Figure3.3.B and C), this 
suggests a cell-intrinsic mechanism of transcriptional regulation and not systemic signals that 
would affect both infected cells and their uninfected neighbors. Future studies will be needed to 
assess the mechanisms of direct viral induction of ISGs in individual infected CD4+ T cells. 
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Some possibilities include sensing of viral capsid by TRIM5α 124, sensing viral RT products by 
IFI16 196, and sensing of viral particle assembly/budding by BST-2/Tetherin 198. The signaling 
cascade that leads to interferon production through the transcription factor IRF3 can also result in 
expression of ISGs without prior interferon signaling 405,406. 
Gene expression: cause or consequence of infection 
 Since qRT-PCR is a snapshot of a particular cell at a particular time, it is not possible to 
track changes in gene expression in a single cell over time. When comparing infected and 
uninfected cells, there is a chance that infection altered the expression of cellular genes, as 
posited above in regard to ISGs. We have evidence suggesting that PD-1 and CXCR5 expression 
is not altered by infection at a bulk level by comparing CD4+ T cells from uninfected animals to 
those from acutely SIV-infected animals. It may be possible to further characterize this at a 
single cell level in vitro by comparing expression levels in many cells before and after infection, 
with the caveat that the same cell cannot be analyzed twice. 
 
4.D. Identification of a novel PD-1+ CXCR5+ CD4+ T cell population in the jejunum—
remaining questions 
Localization and normal biological functions 
 The precise localization of PD-1+ CXCR5+ CD4+ T cells within the jejunum is not 
currently known. Differences in genes that determine germinal center positioning (CCR7, 
GPR183/EBI2, and SAP) between the jejunum population and GC Tfh cells suggests that these 
cells are not located in germinal centers. The general lack of Peyer’s patches in rhesus jejunum 
tissue supports this conclusion as well 151. One possibility is that these are circulating Tfh cells 
like those found in peripheral blood; however, this jejunum population differs from circulating 
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Tfh cells that do not generally express BCL6 protein or the cell surface activation markers PD-1, 
CD69, and ICOS 382. While macroscopically visible Peyer’s patches are rare in jejunum since 
their size and density increases from duodenum to ileum 386,407, scattered small lymphoid nodules 
are occasionally present in histological sections from jejunum 151. It is possible that these diffuse 
lymphoid aggregates harbor this jejunum Tfh-like population. 
Tfh cells found in lymphoid tissue but not in germinal centers could be newly activated 
Tfh cells in the process of transiting to a germinal center or germinal center Tfh cells transiting 
to a new germinal center. Very little is known about transiting Tfh cells and what markers could 
define them. These cells could also be Tfh cells destined to provide help outside of germinal 
centers, a role that has been proposed 152 but little studied.  
 Since the populations of PD-1+ CXCR5+ memory CD4+ T cells in jejunum has not been 
previously described, the normal biological functions of this population are not known. Other 
than localization markers, we showed very strong similarity in gene expression profiles of PD-1+ 
CXCR5+ jejunal CD4+ T cells with germinal center Tfh cells from lymph nodes. Tfh cells in 
Peyer’s patches are known to be tightly involved in IgA antibody responses 408. IgA comprises 
the majority of all immunoglobulin produced in mammals, and since it can be secreted, is 
important for neutralizing pathogens and controlling commensal microbiota in intestinal lumen 
409. The general process of an IgA response involves induction in Peyer’s patches, plasmablast 
recirculation and homing to intestinal mucosa, differentiation to plasma cells producing IgA, and 
secretion of IgA through the intestinal epithelium 409. The majority of IgA sequences in gut 
lamina propria are highly mutated suggesting a germinal center origin, and Peyer’s patch 
germinal center formation and maintenance is dependent on CD4+ T cells 408.  
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In addition to the highly mutated germinal center B cells, some T-dependent B cell 
differentiation occurs extrafollicularly (in the outer T zone of secondary lymphoid tissues) and 
produces short lived plasmablasts producing unmutated antibody that can be important for early 
protection against microbes 410. Like germinal center Tfh cells, the T cells priming B cells 
extrafollicularly have been shown to require BCL6 and IL-21 expression 411. However, unlike 
the jejunum Tfh cells we describe, these cells are PD-1low 411. 
Consequences of SIV infection 
 Many unanswered questions remain regarding possible consequences of the PD-1+ 
CXCR5+ cells becoming infected with SIV, especially since their function is not currently 
known. We currently do not know if these cells become depleted during SIV infection, though 
the observed level of direct viral infection and non-statistically significant decreases comparing 
uninfected to seven and 10 day post infection animals (Supplemental Figure 3.2) suggest they 
do. Additionally, a study failed to find PD-1high CD4+ T cells in the jejunum of chronically 
infected animals 350, but without characterizing uninfected animals as a comparison, they could 
not conclude whether this was true depletion or lack of PD-1high cells in normal conditions. 
Acute SIV infection depleted Tfh cells from the spleen 272 and lymph nodes 412; however, other 
studies have observed an accumulation of Tfh cells in some animals during chronic SIV infection 
despite high levels of infection 412,413, and depletion again in terminal stages of disease 412. 
Studying the dynamics of this population over the course of infection will thus be important. 
 A critical remaining question is if these cells become latently infected. The identity of the 
latent reservoir has been under intense investigation since knowing the characteristics of cells 
that are a source of virus could lead to targeted strategies designed to eliminate them. There are 
many recent studies implicating Tfh cells in lymph nodes as latently infected in SIV and HIV 
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infections 271,391,414, but since the population described here does not reside in a lymph node 
protected from CTL responses, it is unclear if they persist while infected. 
Implications for pathogenesis 
 The extremely high level of infection of the PD-1+ CXCR5+ cells from jejunum suggest 
that they are highly susceptible to infection. They could be initial target cells in intravenous 
infection or, if they are also located in rectal/vaginal mucosa, a target in sexual transmission. 
Their location in intestinal mucosa places them in close proximity to other activated CD4+ T 
cells to which infection could be spread, assuming their high level of viral RNA production 
results in similarly high levels of virion production.  
 Infection that results in depletion could impair their normal functions. For example, if 
these cells are newly activated Tfh cells destined to transit to a lymph node to induce germinal 
center formation, this process could be disrupted. IgA responses in both humans and 
chimpanzees with HIV as well as macaques with SIV are weak or absent despite excellent IgG 
responses 415-418 while other mucosal infections induce preferential IgA responses 419. Depletion 
of mucosal Tfh cells could explain this dichotomy. Additionally, a major source of pathogenesis 
in HIV appears to be due to microbial translocation (reviewed in 181), and loss of IgA responses 
could contribute to the loss of barrier function seen early in infection. 
Implications for prevention/treatment 
 Better understanding of the functions of these PD-1+ CXCR5+ cells could impact 
prevention and treatment of HIV. Preventing their infection though a vaccine or drug treatment 
could result in better antibody responses, importantly perhaps highly hypermutated broadly 
neutralizing antibodies. It would be interesting to determine if antiretroviral treatment can 
prevent their infection since evidence of mucosal replication of HIV is sometimes still seen even 
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in patients on treatment 420,421.  Finally, if these cells are latently infected, understanding what 
approaches can eliminate them could impact HIV cure research. 
  
4.E. Future Directions 
Further characterization of the PD-1+ CXCR5+ population from jejunum is currently 
underway. To determine if this population produces IL-21 protein, a functional mark of Tfh 
cells, we are currently optimizing an intracellular cytokine staining panel for IL-21, IL-2, and 
IFN-γ. Four uninfected jejunum samples have been obtained for testing. We anticipate they will 
produce IL-21 when stimulated since they produce IL-21 mRNA (Figure 3.5.B). 
 Another critical aspect of the study involves identification of the localization of PD-1+ 
CXCR5+ CD4+ T cells in the gut. Jejunum and lymph node formalin-fixed and paraffin-
embedded tissue samples from uninfected and SIV-infected animals that have been sent to the 
lab of Ashley Haase (University of Minnesota) for immunohistochemistry analysis. We plan to 
analyze the tissue architecture with respect to the location of this cell population and use in situ 
hybridization to identify virus-infected cells.  
 To verify the susceptibility of the PD-1+ CXCR5+ population to SIV infection and to 
more rigorously test if infection changes expression of PD-1 or CXCR5, we plan to perform an 
in vitro infection with GFP-tagged SIV. We will assess gene expression before and after 
infection, and measure the extent of infection in defined PD-1 and CXCR5 subpopulations. 
 Finally, if it is possible to find a source of samples, determining if there is an equivalent 
population in humans would be important to demonstrate the relevance of our findings.  
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Appendix A: Supplemental Figures 
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Supplemental Figure 3.1. Quality control procedure for single cell expression profiling. 
Visual inspection of each capture site allows tracking of the number of cells captured (A) and the 
live/dead staining status (B). Histogram displaying the number of genes detectably expressed in 
all wells (C). After removal of wells with fewer than 4 genes expressed, there are two clear 
populations of cells (D), those that correlate with dead staining expressing fewer than 20 genes 
(E) and those that correlate with live staining expressing more than 20 genes (F). Microscope 
staining alone allows some cells that stained dead (circled in G) and stained live (circled in H) to 
be incorrectly categorized from a transcriptional standpoint. 
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Supplemental Figure 3.1. (Continued) 
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Supplemental Figure 3.2. Frequency of PD-1+ CXCR5+ population in SIV infection. 
Changes were non-statistically significant (T-test). 
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